Diketone compounds, preparation method therefor and use thereof
By synthesizing diketone compounds, the problem of insufficient activity of existing eEF2K-targeting compounds has been solved, enabling effective treatment of malignant tumors, especially triple-negative breast cancer.
Patent Information
- Application Number
- PCT/CN2024/094552
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2024-05-21
- Publication Date
- 2024-11-28
AI Technical Summary
Existing small molecule compounds targeting eEF2K have weak cell-inhibiting activity or low degradation rates, and cannot effectively treat malignant tumors.
A diketone compound was designed and synthesized, and a compound with strong eEF2K binding ability and in vitro cell inhibitory activity was prepared through diazotization coupling reaction, cyclization reaction, substitution reaction and acyl chloride reaction.
These diketone compounds exhibit strong eEF2K affinity and anti-malignant tumor cell activity, with low normal cytotoxicity, making them suitable for the treatment of malignant tumors such as triple-negative breast cancer.
Smart Images

Figure CN2024094552_28112024_PF_FP_ABST
Abstract
Description
A diketone compound and its preparation method and application Technical Field
[0001] The present invention relates to the technical field of medicinal chemistry, and in particular to a diketone compound or its isomer, a preparation method thereof, and use thereof in preparing a drug for preventing and / or treating malignant tumors associated with eEF2K. Background Art
[0002] According to 2020 statistics from the World Health Organization, there were 19.3 million new cancer cases and 9.96 million new deaths worldwide. In 2022, my country saw 4 million new cancer cases and 3 million new deaths. In the same year, statistics on the incidence of different types of cancer in my country showed that lung cancer ranked first, followed by colon cancer, stomach cancer, breast cancer, and liver cancer. This demonstrates that malignant tumors have become a serious threat to the health of the Chinese people.
[0003] Currently, commonly used anti-tumor drugs include biological alkylating agents, antimetabolites, antibiotics, natural products and their derivatives, and protein tyrosine kinase inhibitors. However, these anti-malignant tumor drugs have numerous drawbacks. For example, biological alkylating agents, while inhibiting tumor cells, also inhibit other rapidly proliferating cells and are prone to developing drug resistance. Antimetabolites have a narrow anti-tumor spectrum; antibiotics have a high myelosuppressive toxicity. Natural products are limited in source and difficult to synthesize. Therefore, there is an urgent need to develop anti-tumor drugs with low toxicity, high activity, and simple sources.
[0004] Eukaryotic elongation factor 2 kinase (eEF2K), a member of the α-kinase family of atypical kinases, is a calcium / calmodulin-dependent kinase with unique structure and function. It participates in the calmodulin-mediated signaling pathway in the human body, catalyzing the phosphorylation of the Thr56 site of eukaryotic elongation factor-2 (eEF2) and leading to its inactivation, thereby inhibiting the protein peptide chain elongation process of mRNA translation.
[0005] eEF2K is highly expressed in various malignant tumor cells, such as lung, colon, breast, and esophageal cancers. When normal tissues experience nutrient deprivation, mTORC and Erk are inhibited, and the AMP / ATP ratio increases, thereby activating eEF2K to phosphorylate eEF2 and inhibit protein synthesis, promoting cellular autophagy, reducing tumor cells' nutrient requirements, and ultimately improving their survival. Conversely, inhibiting eEF2K inhibits tumor cell growth (Lung Cancer, 2018, 124, 31–39; Oncotarget, 2017, 8, 11641–11658; Radiother Oncol. 2017, 124, 439–447; Apoptosis. 2014, 19, 241–258; Cell, 2013, 153, 1064–1079). In summary, eEF2K is a very potential target for the treatment of malignant tumors, and small molecule compounds targeting eEF2K protein will be expected to alleviate or treat malignant tumors.
[0006] SUMMARY OF THE INVENTION Technical issues
[0007] At present, a variety of small molecule compounds targeting eEF2K have been discovered, including inhibitors and protein degradation targeting complexes (PROTACs) (Int. J. Mol. Sci. 2021, 22, 2408), such as the selective eEF2K inhibitor A-484954 developed by Abbott, which inhibits eEF2K by competing with ATP for binding to eEF2K (IC 50 =0.28 μM), but the cell activity was weak (IC 50 >20 μM) (J. Biol. Chem. 2011, 286, 43951–44398; Bioorg. Med. Chem. 2014, 22, 4910–4916). Furthermore, PROTAC derivatives of A-484954 were discovered, with a maximum eEF2K degradation rate (Dr) of only 56.7%. Therefore, these compounds are currently used only as pharmacological tools. Technical Solutions
[0008] To this end, the technical problem to be solved by the present invention is to overcome the shortcomings of the existing small molecule compounds targeting eEF2K in the prior art, such as weak cell inhibitory activity or low degradation rate. In order to solve the above technical problems, the present invention provides a diketone compound and its anti-tumor application related to eEF2K.
[0009] The first object of the present invention is to provide a diketone compound, the structural formula of which is shown in Formula A:
[0010] in, Independently selected from substituted or unsubstituted aryl or heteroaryl; X is a carbonyl or alkyl, Y is a substituted or unsubstituted alkyl, and Z is N or CH; preferably, X is a carbonyl C=O, or a C1-C3 chain alkyl, and Y is a substituted or unsubstituted C1-C3 alkyl;
[0011] R1 and R2 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclic group, ester group, substituted or unsubstituted alkenyl group, substituted or unsubstituted alkynyl group, substituted or unsubstituted aryl group, and both cannot be hydrogen at the same time; or R1 and R2 together with the nitrogen atom to which they are attached form a substituted or unsubstituted heterocyclic group; R1 and R2 may be the same or different;
[0012] Furthermore, in the substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl, the number of carbon atoms of the alkyl, alkenyl, and alkynyl groups is 1 to 10; in the substituted or unsubstituted heterocyclic group, the heterocyclic ring is a 3-8-membered monocyclic ring or a 6-20-membered polycyclic ring; in the substituted alkyl, substituted heterocyclic group, substituted alkenyl, substituted alkynyl, and substituted aryl groups, the substituents are independently selected from one or more of halogen, alkyl, alkoxy, haloalkyl, silyl, aralkyl, heteroaryl, hydroxyl, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminoalkyl, aminoalkoxy, amino, alkylamino, hydroxyalkylamino, aminoalkylamino, alkoxyacyl, alkoxycarbonylamino, cyano, acyloxy, acyl, sulfonyl, carbamoyl, sulfonylamino, nitro, urea, and thiourea.
[0013] In one embodiment of the present invention, R1 and R2 are substituted by multiple R3 groups; each R3 group is selected from one or more of halogen, C1-C6 alkyl, haloalkyl, silyl, aralkyl, heteroaryl, alkoxy, hydroxy, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminoalkyl, aminoalkoxy, amino, alkylamino, hydroxyalkylamino, aminoalkylamino, alkoxyacyl, alkoxycarbonylamino, cyano, acyloxy, acyl, sulfonyl, sulfonylamino, urea, thiourea, nitro, and carbamoyl. The number of R3 groups can be 1-3, specifically 1, 2, or 3. R1 and R2 being substituted by multiple R3 groups means that the heterocyclic group formed by R1 and R2 together with the nitrogen atom to which they are attached is substituted by multiple R3 groups, or that R1 and R2 are independently substituted by multiple R3 groups.
[0014] Further, R1 and R2 are the same or different and are independently selected from hydrogen, C1-C10 alkyl, substituted or unsubstituted aryl, which may be optionally substituted by 1-3 identical or different R3, but R1 and R2 cannot be hydrogen at the same time; or R1 and R2 together with the nitrogen atom to which they are attached form a substituted or unsubstituted 3-10 membered heterocyclic group, including forming a monocyclic, bicyclic or tricyclic ring, which may be a bridged ring or a spirocyclic ring, which may optionally include 0, 1 or 2 carbon-carbon double bonds, and further is a 5-7 membered heterocyclic group, preferably a 6-membered heterocyclic group. The structural formula (A') is shown below, and the dotted line in the molecular formula indicates that R1 and R2 can form a ring:
[0015] R3 is halogen, C1-C6 alkyl, haloalkyl, silyl, aralkyl, heteroaryl, alkoxy, hydroxy, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminoalkyl, aminoalkoxy, amino, alkylamino, hydroxyalkylamino, aminoalkylamino, alkoxyacyl, alkoxycarbonylamino, cyano, carboxyl, acyloxy, acyl, sulfonyl, sulfonamido, urea, nitro, thiourea and carbamoyl; further, R3 is halogen, C1-C6 alkyl, cyano, acyloxy, acyl, sulfonyl and carbamoyl; further, R3 is fluorine, acyloxy, carbamate. In addition to the nitrogen atom to which R1 and R2 are attached, the heterocyclic group optionally includes 0, 1 or 2 carbon-carbon double bonds, and the heterocyclic group and heteroaryl.
[0016] In the present invention, alkyl refers to branched alkyl, straight-chain alkyl, cycloalkyl, halogenated alkyl, nitrogen-containing alkyl, aralkyl, etc.; aryl refers to substituted or unsubstituted aryl or heteroaryl.
[0017] Furthermore, the alkyl group may specifically be a branched, straight, or cycloalkyl group of C3, C4, C5, C6, C7, C8, C9, or C10. The alkyl group in the C3-C10 nitrogen-containing alkyl group may be C3, C4, C5, C6, C7, C8, C9, or C10, optionally containing 0-4 heteroatoms selected from N and O (preferably 1-4), including piperidine rings, piperazine rings, homopiperazine rings, morpholine rings, and the like. The aralkyl group may be a phenyl ring, a naphthalene ring, a biphenyl ring, or a nitrogen-containing heterocycle such as a pyridine ring.
[0018] Furthermore, the C1-C6 alkyl group may be a C1, C2, C3, C4, C5, or C6 alkyl group.
[0019] Furthermore, the C1-C10 alkyl group may be a cycloalkyl group, a chain alkyl group, a halogenated alkyl group, a nitrogen-containing alkyl group or an aryl alkyl group of C1, C2, C3, C4, C5, C6, C7, C8, C9, or C10; the C1-C6 alkyl group may be a cycloalkyl group or a chain alkyl group of C1, C2, C3, C4, C5, or C6; and the C1-C3 alkyl group may be a cycloalkyl group or a chain alkyl group of C1, C2, or C3.
[0020] In one embodiment of the present invention, the substituted or unsubstituted aryl or heteroaryl group is a substituted or unsubstituted benzene ring, naphthalene ring, biphenyl ring, or an aromatic heterocycle composed of one or more N, O, S, wherein N, O, S may exist alone, simultaneously, or in pairs. Specifically, the substituted or unsubstituted heteroaryl group is selected from a substituted or unsubstituted pyrrole ring, pyrazole ring, furan ring, thiophene ring, thiazole ring, isothiazole ring, oxazole ring, isoxazole ring, imidazole ring, pyridine ring, ring, pyrazine ring, pyrimidine ring, pyridazine ring, triazole, naphthalene ring, benzoaromatic heterocycle (not limited to quinoline ring, isoquinoline ring, indole ring, quinazoline, benzofuran ring, benzothiophene ring, benzothiazole ring, benzoxazole ring, benzisoxazole ring, benzothiazole ring, indazole ring, benzimidazole ring, benzotriazole ring), benzocycloalkanes (not limited to indoline ring, isoindoline ring, tetrahydroisoquinoline ring, tetrahydroquinoline ring, benzazepine, benzoxazepine, benzoxazepine), etc. The substituents in the substituted or unsubstituted aryl or heteroaryl are selected from one or more of hydrogen, alkyl, haloalkyl, silyl, aralkyl, heteroaryl, alkoxy, haloalkoxy, hydroxy, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminealkoxy, amino, aminealkyl, alkylamino, hydroxyalkylamino, aminealkylamino, halogen, cyano, acyloxy, carbamoyl, sulfonylamino, urea, thiourea, nitro, acyl and sulfonyl.
[0021] In one embodiment of the present invention, The substituted or unsubstituted aryl or heteroaryl group is selected from a substituted or unsubstituted benzene ring, a naphthalene ring, a quinoline ring, an isoquinoline ring, an indole ring, a quinazoline, an indoline ring, an isoindoline ring, a tetrahydroisoquinoline ring, a tetrahydroquinoline ring, a benzazepine, a benzoxazepine, and a benzoxazepine; further preferably 3,4-dimethylphenyl, 5,6,7,8-tetrahydronaphthalene-2-amine, 2,3-dihydro-1H-indene-5-amine, tetrahydroisoquinolinyl, and tetrahydroquinolinyl. is selected from substituted or unsubstituted aryl or heteroaryl groups, selected from substituted or unsubstituted phenyl groups, naphthalene rings, biphenyl rings, pyridine rings, triazoles, and the substituent groups are selected from one or more of halogen, alkyl, alkoxy, nitro, amino, hydroxyalkoxy, alkoxyalkoxy, acyloxy, acyl and sulfonyl groups. Preferred are phenyl, 3-fluorophenyl, 2-fluorophenyl, 2-methylphenyl, 3-methylphenyl, 3-chlorophenyl, 2-chlorophenyl, 3-methoxyphenyl, 2-methoxyphenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 3-nitrophenyl, 2-nitrophenyl, 3-hydroxyphenyl, 2-hydroxyphenyl, 3-aminophenyl, 2-aminophenyl, hydroxyethoxyphenyl, methoxyethoxyphenyl, pyridyl, and triazolyl.
[0022] Preferably, the diketone compound is the following compound (the compound prepared in the embodiment of the present invention):
[0023] The second object of the present invention is to provide a method for preparing the diketone compound, comprising the following preparation method:
[0024] Method 1:
[0025] (1) reacting the compound represented by Formula A1 with the compound represented by Formula A2 by diazotization coupling reaction to obtain the compound represented by Formula A3;
[0026] (2) The compound represented by Formula A3 undergoes ring closure under acidic conditions to obtain the compound represented by Formula A4, and the compound represented by Formula A4 undergoes a substitution reaction with a halogenated hydrocarbon under alkaline conditions to obtain the compound represented by Formula A5;
[0027] (3) The cyano group of the compound represented by formula A5 is hydrolyzed under acidic conditions to obtain a compound represented by formula A6 containing a carboxylic acid;
[0028] (4) The compound represented by Formula A6 is prepared into an acyl chloride compound represented by Formula A7, and reacted with an amine compound to obtain the compound represented by Formula A, i.e., the diketone compound;
[0029] Or method 2:
[0030] (1) reacting the compound represented by formula B1 with the compound represented by formula B2 to obtain the compound represented by formula B3;
[0031] (2) the compound represented by formula B3 reacts under alkaline conditions to obtain the compound represented by formula B4, and the compound represented by formula B4 reacts to obtain the compound represented by formula B5;
[0032] (3) reacting the compound represented by formula B5 to obtain the compound represented by formula B6 containing a carboxylic acid; or reacting the compound represented by formula B5 with an amine compound to obtain the diketone compound;
[0033] (4) reacting the compound represented by formula B6 with an amine compound to prepare the diketone compound;
[0034] Or method three:
[0035] (1) reacting the cyano group of the compound represented by formula A5 to obtain the compound represented by formula C2 containing an amino group;
[0036] (2) preparing the diketone compound from the compound represented by formula C2;
[0037] The structural formula of the above compound is shown below:
[0038] The structural formula of the amine compound is shown below:
[0039] The structural formula of halogenated hydrocarbons is shown below:
[0040] In the above structural formula, the selection of substituents is consistent with the above.
[0041] In the above technical solution, in method 1, the molar ratio of the compound represented by formula A1 to the compound represented by formula A2 is 1:1-1:2, the acidic condition is a pH value of 1-4; the alkaline condition is a pH value of 8-10, and the compound represented by formula A6 is subjected to an acyl chloride reaction in the presence of a catalyst to prepare an acyl chloride compound represented by formula A7;
[0042] In method 2, the reaction of the compound represented by formula B1 and the compound represented by formula B2 is carried out in the presence of a copper salt catalyst and a base catalyst, the compound represented by formula B3 is reacted in the presence of an inorganic base compound to obtain the compound represented by formula B4, and the compound represented by formula B4 is reacted in the presence of a phosphorus catalyst to obtain the compound represented by formula B5;
[0043] In method three, the cyano group of the compound represented by formula A5 reacts with hydrogen and a precious metal catalyst to obtain an amino-containing compound represented by formula C2, and the compound represented by formula C2 reacts with an amine compound to prepare the diketone compound, or the compound represented by formula C2 reacts with a carboxylic acid compound to prepare the diketone compound.
[0044] Furthermore, the specific preparation method of the diketone compound described in Method 1 is as follows:
[0045] Step 1: Dissolve the substituted amine compound represented by Formula A1 in a mixture of concentrated hydrochloric acid and water, and add a diazotizing agent solution under ice bath; then add an aqueous solution of N-cyanourethane A2 and sodium acetate to the reaction mixture, and after completion of the reaction, obtain the compound represented by Formula A3;
[0046] Step 2: Dissolve the compound represented by Formula A3 and a base in an acid and reflux at high temperature to cause a ring-closure reaction. After the reaction is complete, the compound represented by Formula A4 is obtained.
[0047] Step 3: Dissolve the compound represented by Formula A4 in an organic solvent, and react with a halogenated hydrocarbon under alkaline conditions to obtain a compound represented by Formula A5;
[0048] Step 4: Carboxylating the compound represented by Formula A5 in the presence of at least one of acetic acid, concentrated hydrochloric acid, and sulfuric acid to obtain a compound represented by Formula A6 containing a carboxylic acid;
[0049] Step 5: Under nitrogen protection, the compound represented by Formula A6 is reacted with at least one of oxalyl chloride, thionyl chloride, phosphorus trichloride or phosphorus pentachloride in the presence of a catalyst to undergo chlorination reaction, and after complete reaction, the compound represented by Formula A7 is obtained.
[0050] Step 6: reacting the compound represented by formula 7 with an amine compound to obtain a compound represented by formula A.
[0051] In one embodiment of the present invention, in step 1, the diazotization reagent in the diazotization reagent solution is selected from one or more of sodium nitrite, tert-butyl nitrite, isoamyl nitrite, nitrosylsulfuric acid and nitroso tetrafluoroborate.
[0052] Furthermore, the reagent of the diazotization reagent solution is one or more of aqueous sulfuric acid, hydrochloric acid, hydrobromic acid, glacial acetic acid, acetone, tetrahydrofuran, and toluene.
[0053] In one embodiment of the present invention, in step 1, the reaction conditions are: reaction temperature -5°C to 5°C, and reaction time is 2 to 4 hours.
[0054] In one embodiment of the present invention, in step 2, the conditions for the ring-closure reaction are: reaction temperature 90° C.-120° C., and reaction time 4 to 8 h.
[0055] In one embodiment of the present invention, in step 2, the base is selected from one or more of sodium acetate, potassium carbonate, potassium acetate, sodium carbonate, triethylamine and DIPEA.
[0056] In one embodiment of the present invention, in step 2, the acid is selected from one or more of glacial acetic acid, formic acid, methanesulfonic acid and trifluoroacetic acid.
[0057] In one embodiment of the present invention, in step 3, the reaction temperature is 10° C. to 40° C., and the reaction time is 6 h to 12 h.
[0058] In one embodiment of the present invention, in step 3, the organic solvent is selected from one or more of acetonitrile, acetone, DMF, tetrahydrofuran, ethanol and DMSO.
[0059] In one embodiment of the present invention, in step 3, the pH value of the alkaline condition is 7-11.
[0060] In one embodiment of the present invention, in step 5, the catalyst in the acyl chlorination reaction is DMF; the reaction solvent is DCM and acetonitrile; and the reaction time is 10-40°C.
[0061] In one embodiment of the present invention, in step 6, the reaction conditions are: using a base selected from triethylamine or DIPEA, the solvent used is one or more of DCM, DMF and DCE, and the reaction temperature is -10°C to 10°C.
[0062] Furthermore, in the preparation method of diketone compounds described in Method 2, the copper salt catalyst is an organic copper salt catalyst, the base catalyst is an organic base catalyst, the inorganic base compound is an alkali metal carbonate, and the phosphorus catalyst is an inorganic phosphorus compound.
[0063] Furthermore, in the preparation method of the diketone compound described in Method 2, the noble metal catalyst is a palladium catalyst, and the carboxylic acid compound includes 1-methylpiperidine-4-carboxylic acid.
[0064] The third object of the present invention is to provide the use of the diketone compound and its isomers or pharmaceutically acceptable salts or hydrates in the preparation of a malignant tumor drug or a eukaryotic elongation factor kinase 2 (eEF2K) inhibitor. The malignant tumor drug refers to a drug for treating malignant tumors.
[0065] In one embodiment of the present invention, the malignant tumor is selected from breast cancer, colon cancer, lung cancer, esophageal cancer, breast cancer, etc.
[0066] The present invention discloses an anti-tumor drug, the active ingredient of which includes the above-mentioned diketone compound and its isomers or pharmaceutically acceptable salts or hydrates. The diketone compound described in the present invention can be used alone as the active ingredient of the anti-tumor drug, or can be used in combination with other drugs as the active ingredient of the anti-tumor drug. Beneficial effects
[0067] The above technical solution of the present invention has the following advantages over the prior art:
[0068] The present invention designed and synthesized compounds with the general formula A and found that these compounds exhibit strong binding ability and in vitro cytostatic activity against eEF2K, with good selectivity. This invention reveals and elucidates the relationship between structure and activity of these compounds on a broader scale, in a more in-depth and comprehensive manner, and has significant application value.
[0069] The present invention designs diketone compounds having the general structure A and discovers that compounds with this structure have strong affinity for eEF2K and exhibit potent anti-malignant tumor cell activity, while also exhibiting low toxicity to normal cells and a good safety profile. This invention reveals and elucidates the relationship between the structure and activity of diketone compounds on a larger scale and in a more in-depth and comprehensive manner, thus possessing significant application value. The diketone compounds of the present invention, when acting on eEF2K, can be used to effectively treat malignant tumors (e.g., triple-negative breast cancer). BRIEF DESCRIPTION OF THE DRAWINGS
[0070] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below based on specific embodiments of the present invention in conjunction with the accompanying drawings, wherein:
[0071] FIG1 is a schematic diagram of the synthesis of diketone compounds of the present invention.
[0072] FIG2 is a schematic diagram of the synthesis of compounds Z82 and Z83 described in examples of the present invention.
[0073] FIG3 is a schematic diagram of the synthesis of compounds Z86, Z87, Z88, and Z89 described in the examples of the present invention.
[0074] Figure 4 (A) shows the inhibitory activity of Z19 and Z37 in Test Example 1 of the present invention on other breast cancer cells; (B) shows the degradation effect of Z19 and Z37 in Test Example 3 of the present invention on eEF2K protein; (C) shows the SPR binding experiment of representative compounds in the examples of the present invention and eEF2K protein.
[0075] Figure 5 (A) and (B) show the in vivo anti-tumor effects of Z19 in Test Example 4 of the present invention; (C) and (D) show the effects of Z19 in Test Example 4 of the present invention on the body weight and major organs of mice. Modes for Carrying Out the Invention
[0076] The present invention will be further described below with reference to the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it. However, the embodiments are not intended to limit the present invention.
[0077] In the following examples of the present invention, the structures of the compounds were determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR was determined using an Agilent 300 MHz or 600 MHz instrument, with deuterated dimethyl sulfoxide (DMSO-d6) or deuterated chloroform (CDCl3) as the solvent and tetramethylsilane (TMS) as the internal standard. MS was determined using a GCT Premier TM (CI) Measured by mass spectrometry, all sources were CI (70 eV) unless otherwise specified.
[0078] Thin layer chromatography silica gel plates use Yantai Huanghai HSGZ534 or Qingdao GZ534 silica gel plates. The specifications of the silica gel plates used in thin layer chromatography (TLC) are 0.15mm-0.2mm. Column chromatography generally uses Yantai Huanghai 100-200 mesh or 200-300 mesh silica gel as a carrier.
[0079] Unless otherwise specified, the reaction conditions of nitrogen filling refer to that the reaction flask is connected to a nitrogen balloon with a volume of about 1 L, and the reaction conditions are room temperature (rt), and the temperature range is 20-30°C.
[0080] In the following examples of the present invention, all solvents were redistilled before use, and the anhydrous solvents used were obtained by drying according to standard methods.
[0081] Figures 1, 2, and 3 are schematic diagrams of the synthesis of diketone compounds according to the present invention. The following experiments illustrate the technological advancements of the present invention. The structural formulas of the prepared compounds are shown above. The raw materials used in the present invention are all conventional products, and the specific preparation operations and performance testing are conventional techniques. The animal experiments employed met the requirements of Soochow University, and the statistical analysis was performed using conventional methods.
[0082] Example 1
[0083] This example provides a synthesis of a compound, as shown in the schematic diagram below. Taking compound Z1(2-263) as an example, the specific preparation method is as follows. Reaction conditions: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile; (d) HCl, AcOH, 110°C; (e) oxalyl chloride, DMF, DCM, N2; (f) Et3N, DCM, 0°C.
[0084] (1) Synthesis of compound Z1C:
[0085] 5g (41.26mmol) of 3,4-dimethylaniline (Z1A) was placed in a 250mL round-bottom flask, and 60mL of water and 22.5mL of concentrated hydrochloric acid were added. The solution was placed in an ice bath and stirred to cool. Subsequently, 3.94g (57.76mmol) of sodium nitrite was dissolved in 20mL of water and slowly added dropwise to the previous solution for TLC detection. After the reaction of 3,4-dimethylaniline was complete, 6.7g (41.26mmol) of N-cyanoacetylurea (Z1-B) and 10g (123.78mmol) of sodium acetate were dissolved in 50mL of a mixture of pyridine and water (1:1 (v / v)) and added dropwise to the diazonium salt solution under an ice bath. After the reaction was completed, the mixture was filtered, washed with water 3 times, and dried to obtain 10.04g of a yellow solid with a yield of 84.44%. The NMR data of the product were as follows: 1 H NMR(300MHz, DMSO-d6)δ11.95(s,1H),10.42(d,J=4.5Hz,1H),7.50–7.35(m,2H),7.11( d,J=7.9Hz,1H),4.15(tt,J=7.7,4.7Hz,2H),2.18(d,J=11.3Hz,6H),1.41–1.16(m,3H).
[0086] (2) Synthesis of compound Z1D:
[0087] Z1C (10.04 g, 34.82 mmol) and sodium acetate (14.28 g, 174.12 mmol) were placed in a 250 mL round-bottom flask, dissolved in 120 mL of glacial acetic acid, and refluxed at 110°C. After the reaction, a large amount of water was added until no solid precipitated. The mixture was filtered, washed three times with water, and dried to obtain 7.8 g of a pale yellow solid with a yield of 92.46%. The product's NMR data are as follows: 1 H NMR (300MHz, CDCl3) δ9.31 (s, 1H), 7.32 (dd, J = 10.7, 5.0Hz, 3H), 2.40 (s, 6H).
[0088] (3) Synthesis of compound Z1E
[0089] Z1D (1.68 g, 6.94 mmol) and potassium carbonate (1.92 g, 13.87 mmol) were placed in a 250 mL round-bottom flask. 70 mL of acetonitrile was added and stirred in an ice bath. Benzyl bromide was slowly added dropwise. After the reaction, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1 (v / v)) to yield 1.99 g of a white solid in 86.33% yield. The product's NMR data were as follows: 1 H NMR (300MHz, CDCl3) δ7.62–7.49(m,2H),7.34(q,J=2.8Hz,3H),7.26–7.13(m,3H),5.16(s,2H),2.31(s,6H).
[0090] (4) Synthesis of compound Z1F
[0091] Dissolve 1.5 g (4.52 mmol) of compound Z1E in 32 mL of glacial acetic acid, heat with stirring, raise the temperature to 70°C, add 16 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction, evaporate the acetic acid under reduced pressure. Wash the remaining solid once with water and dissolve it in diethyl ether with stirring until a white solid precipitates. Collect the solid by filtration to obtain 1.1 g of a white solid (yield: 69.37%).
[0092] (5) Synthesis of compound Z1G
[0093] Place 100 mg (300.88 μmol) of compound Z1F in a two-necked flask under nitrogen. Pour 2 mL of redistilled DCM into the flask, add one drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0094] (6) Synthesis of Compound Z1
[0095] 3-Piperidinecarboxamide (237.17 μmol) was dissolved in redistilled DCM, and Et3N (474.35 μmol) was added. The mixture was stirred in an ice bath. Z1G was then diluted with DCM and added dropwise to the reaction mixture. After completion of the reaction, the mixture was evaporated under reduced pressure and purified by column chromatography (DCM:MeOH = 80:1 (v / v)) to yield 49 mg of a white solid in a 44.76% yield. The product's NMR data were as follows: 1 H NMR (300MHz, CDCl3) δ7.37(q,J=8.9,8.2Hz,3H),7.22(d,J=8.0Hz,4H),6.98(d,J=8.1Hz, 2H), 6.83 (t, J = 7.3Hz, 1H), 5.03 (s, 2H), 3.72 (s, 4H), 3.14 (d, J = 19.4Hz, 4H), 2.25 (s, 6H).
[0096] Example 2
[0097] This example provides the synthesis of compound Z2, as follows: The synthesis method of compound Z2 refers to the synthesis method of Z1, except that 3-piperidinecarboxamide is replaced by N-phenylpiperazine. The NMR data of the product are: 1 H NMR (300MHz, CDCl3) δ7.27 (dt, J=33.8, 10.1Hz, 10H), 6.95 (d, J=8.1Hz, 2H), 6.80 (t,J=7.3Hz,1H),5.00(s,2H),3.69(s,4H),3.12(d,J=19.8Hz,4H),2.23(s,6H).
[0098] Example 3
[0099] This example provides a method for synthesizing compound Z3, as follows: The method for synthesizing compound Z3 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by o-methoxybenzylamine. The NMR data of the product are: 1 H NMR(300MHz, CDCl3)δ9.22(s,1H),7.62–7.49(m,2H),7.42–7.21(m,8H),6.94( d,J=8.8Hz,2H),5.22(s,2H),4.69(d,J=5.9Hz,2H),3.95(s,3H),2.32(s,6H).
[0100] Example 4
[0101] This example provides a method for synthesizing compound Z4, as follows: The method for synthesizing compound Z4 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by N-ethylpiperazine. The NMR data of the product are as follows: 1 H NMR (300MHz, CDCl3) δ7.70–7.56(m,2H),7.42–7.24(m,6H),5.23(t,J=3.5Hz,2H),3.86(t,J=5.0Hz,2 H),3.50(q,J=4.7Hz,2H),2.66–2.47(m,6H),2.35(q,J=3.1,2.3Hz,6H),1.17(td,J=6.8,3.5Hz,3H).
[0102] Example 5
[0103] This example provides a method for synthesizing compound Z5, as follows: The method for synthesizing compound Z5 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by N-(2-aminoethyl)pyrrole. The NMR data of the product are as follows: 1 H NMR (300MHz, CDCl3) δ8.84(t,J=5.4Hz,1H),7.53(dd,J=6.8,2.8Hz,2H),7.33(dd,J=5.2,2.0Hz,3H),7.2 7–7.16(m,3H),5.19(s,2H),3.64(q,J=6.2Hz,2H),2.87–2.63(m,6H),2.28(s,6H),1.85(d,J=3.8Hz,4H).
[0104] Example 6
[0105] This example provides a method for synthesizing compound Z6, as follows: The method for synthesizing compound Z6 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by 4-morpholinomethylaniline. The NMR data of the product are as follows: 1 H NMR (300MHz, CDCl3) δ10.81 (s, 1H), 7.79–7.37 (m, 8H), 7.29 (d, J = 8.3Hz, 4 H),5.29(s,2H),3.76(s,4H),3.53(s,2H),2.49(s,4H),2.36–2.24(m,6H).
[0106] Example 7
[0107] This example provides a method for synthesizing compound Z7, as follows: The method for synthesizing compound Z7 is similar to that for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced with 4-amino-1-benzylpiperidine. The NMR data of the product are as follows:1 H NMR (300MHz, CDCl3) δ8.69(s,1H),7.53(s,2H),7.32(s,8H),7.21(s,3H),5.19(s,2H),4.02(s ,1H),3.52(s,2H),2.80(s,2H),2.28(d,J=3.6Hz,6H),2.20(s,2H),2.00(s,2H),1.26(s,2H).
[0108] Example 8
[0109] This example provides a method for synthesizing compound Z8, as follows: The method for synthesizing compound Z8 is similar to that for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced with methyl 4-aminobenzoate. The NMR data of the product are as follows: 1 H NMR (300MHz, DMSO-d6) δ10.95(s,1H),7.97(d,J=7.6Hz,2H),7.80(d,J=8.4Hz,2H),7.52–7.18(m,8H),5.07(s,2H),3.83(s,3H),2.26(s,6H).
[0110] Example 9
[0111] This example provides a method for synthesizing compound Z9, as follows: The method for synthesizing compound Z9 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by β-alanine methyl ester hydrochloride. The NMR data of the product are as follows: 1 H NMR (300MHz, DMSO-d6) δ 8.80 (s, 1H), 7.43–7.19 (m, 8H), 5.03 (s, 2H), 3.61 (d, J = 5.1Hz, 3H), 3.48 (q, J = 6.5Hz, 2H), 2.57 (t, J = 6.7Hz, 2H), 2.27 (s, 6H).
[0112] Example 10
[0113] This example provides a method for synthesizing compound Z10.
[0114] (1) Synthesis of compound Z10A
[0115] The synthesis method of compound Z10A refers to the synthesis method of Z1, except that 3-piperidinecarboxamide is replaced by 2-bromoethylamine hydrobromide. The NMR data of the product are: 1H NMR (300MHz, CDCl3) δ9.10 (s, 1H), 7.56 (s, 2H), 7.42–7.28 (m, 3H), 7.25 (d, J = 10.5Hz, 3 H),5.28–5.17(m,2H),3.90(d,J=6.8Hz,2H),3.58(d,J=5.7Hz,2H),2.38–2.22(m,6H).
[0116] (2) Synthesis of compound Z10
[0117] Dissolve 50 mg (109.3 μmol) of compound Z10A in 3 mL of acetonitrile, add 71.24 mg (218.60 μmol) of cesium carbonate, and stir at reflux. After the reaction is complete, evaporate under reduced pressure and purify by column chromatography (DCM:MeOH = 80:1) to obtain 18 mg of a white solid with a yield of 43.74%. 1 H NMR (300MHz, CDCl3) δ7.52 (d, J = 6.0 Hz, 2H), 7.25 (s, 3H), 7.14 (s, 3H), 5.14 (s, 2H), 4.35 (t, J = 9.7Hz, 2H), 4.11 (t, J = 9.8Hz, 2H), 2.22 (s, 6H).
[0118] Example 11
[0119] This example provides a synthesis of a compound, as shown in the schematic diagram below. Using compound Z11 as an example, the specific preparation method is as follows. The reaction conditions are: (a) K2CO3, iodomethane, acetonitrile, rt; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N2, rt; (d) piperidine, Et3N, DCM, 0°C.
[0120] (1) Synthesis of compound Z11-A
[0121] Compound Z1-D (Z1D), 400 mg (1.65 mmol), and 456.43 mg (3.30 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask. 20 mL of acetonitrile was added and stirred in an ice bath. Methyl iodide was slowly added dropwise. After completion of the reaction, the product was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to yield 220 mg of a white solid in a 51.99% yield.
[0122] (2) Synthesis of compound Z11-B
[0123] Dissolve 220 mg (858.49 μmol) of Z11-A in 10 mL of glacial acetic acid, heat with stirring, raise the temperature to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction, evaporate the acetic acid under reduced pressure. Wash the remaining solid once with water and dissolve it in diethyl ether with stirring until a white solid precipitates. Collect the solid by filtration to obtain 204 mg of a white solid (86.33% yield).
[0124] (3) Synthesis of compound Z11-C
[0125] Place 204 mg (741.11 μmol) of compound Z11-B in a two-necked flask under nitrogen. Pour 2 mL of redistilled DCM into the flask, add one drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0126] (4) Synthesis of compound Z11
[0127] Piperidine (741.11 μmol) was dissolved in redistilled DCM, and Et3N (1.48 mmol) was added. The mixture was stirred in an ice bath. Compound Z11-C was then diluted with DCM and added dropwise to the reaction mixture. After completion of the reaction, the mixture was evaporated under reduced pressure and purified by column chromatography (PE:EA = 3:1) to afford 170 mg of a white solid in a 57.28% yield. 1 H NMR (500MHz, CDCl3) δ7.59 (dd, J=7.9, 2.2Hz, 1H), 7.41 (d, J=2.1Hz, 1H), 7.17 (dq, J=8.0, 1.0Hz, 1H), 3. 62–3.54(m,2H),3.53–3.45(m,2H),3.45(s,3H),2.28(d,J=1.1Hz,3H),2.23(s,2H),1.78–1.68(m,6H).
[0128] Example 12
[0129] Taking compound Z12 as an example, the specific preparation method is as follows. The reaction conditions are: (a) K₂CO₃, acetonitrile, 3-fluorobenzyl bromide; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N₂, rt; and (d) N-(propyl-2-yn-1-yl)piperidine-3-carboxamide, Et₃N, DCM, 0°C.
[0130] (1) Synthesis of compound Z12-A
[0131] Compound Z1-D (1.68 g, 6.94 mmol) and potassium carbonate (1.92 g, 13.87 mmol) were placed in a 250 mL round-bottom flask. 70 mL of acetonitrile was added and stirred in an ice bath. 3-Fluorobenzyl bromide was slowly added dropwise. After the reaction, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to yield 1.90 g of a white solid in a 78.20% yield.
[0132] (2) Synthesis of compound Z12-B
[0133] Dissolve 1.5 g (4.06 mmol) of Z12-A in 32 mL of glacial acetic acid, heat with stirring, raise the temperature to 70°C, add 16 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction, evaporate the acetic acid under reduced pressure. Wash the remaining solid once with water and dissolve it in ether with stirring until a white solid precipitates. Collect the solid by filtration to obtain 1.1 g of a white solid (yield: 69.56%).
[0134] (3) Synthesis of compound Z12-C
[0135] Place 100 mg (270.74 μmol) of intermediate Z12-B in a two-necked flask under nitrogen. Pour 2 mL of redistilled DCM into the flask, add one drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0136] (4) Synthesis of compound Z12
[0137] The synthesis method of compound Z12 is the same as that of Z1 (2-263), except that 3-piperidinecarboxamide is replaced by N-(propyl-2-yn-1-yl)piperidine-3-carboxamide, and Z1-G is replaced by Z12-C. 1H NMR(500MHz, CDCl3)δ7.59(dd,J=7.9,2.2Hz,1H),7.44–7.39(m,2H),7.34(td,J=8.0,5.0Hz,1H),7.17(dq ,J=8.0,1.0Hz,1H),7.12(ddtd,J=7.8,2.9,1.9,0.9Hz,2H),7.03(tdd,J=7.9,1.9,1.2Hz,1H),5.06(s,2H) ,3.97–3.86(m,2H),3.84(dd,J=12.4,4.9Hz,1H),3.65–3.57(m,2H),3.60–3.53(m,1H),2.60(tt,J=6.0,4 .8Hz,1H),2.33(t,J=3.0Hz,1H),2.28(d,J=1.1Hz,3H),2.23(s,1H),1.89–1.71(m,3H),1.74–1.64(m,1H).
[0138] Example 13
[0139] This example provides a method for synthesizing compound Z13. Compound Z1-E (Z1E, 100 mg, 300.88 mmol) was dissolved in 2 mL of ethanol and stirred at 0°C. 6 mg of NaOH and 17.47 mg of DMSO were added and the mixture was allowed to react overnight. After the reaction, the ethanol was evaporated under reduced pressure, dissolved in DCM, washed with water 2-3 times, washed once with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The solid was purified by column chromatography to obtain 50 mg of a white solid with a yield of 47.43%. The NMR data of the product are as follows: 1 H NMR (300MHz, CDCl3) δ8.43 (s, 1H), 7.50–7.44 (m, 2H), 7.30–7.25 (m, 3H), 7.19 (d, J = 2.1Hz, 3H), 5.92 (s, 1H), 5.15 (s, 2H), 2.22 (d, J = 3.2Hz, 6H).
[0140] Example 14
[0141] This example provides a method for synthesizing compound Z14, which is as follows: The method for synthesizing compound Z14 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by dimethylamine hydrochloride. The NMR data of the product are as follows: 1H NMR(300MHz,Chloroform-d)δ7.56(s,2H),7.37–7.30(m,3H),7.23(d,J=11.3Hz,3H ), 5.19 (d, J = 3.2Hz, 2H), 3.12 (d, J = 2.5Hz, 3H), 3.03 (d, J = 2.6Hz, 3H), 2.30 (s, 6H).
[0142] Example 15
[0143] Taking compound Z15 as an example, the specific preparation method is as follows: Reaction conditions: (a) K2CO3, iodomethane, acetonitrile, rt; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N2, rt; (d) ethyl 3-piperidinate, Et3N, DCM, 0°C.
[0144] (1) Synthesis of compound Z15-A
[0145] Compound Z1-D (Z1D, 400 mg, 1.65 mmol) and 456.43 mg (3.30 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask. 20 mL of acetonitrile was added and stirred in an ice bath. Methyl iodide was slowly added dropwise. After completion of the reaction, the product was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to yield 220 mg of a white solid in a 51.99% yield.
[0146] (2) Synthesis of compound Z15-B
[0147] Dissolve 220 mg (858.49 μmol) of Z15-A in 10 mL of glacial acetic acid, heat with stirring, raise the temperature to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction, evaporate the acetic acid under reduced pressure. Wash the remaining solid once with water and dissolve it in diethyl ether with stirring until a white solid precipitates. Collect the solid by filtration to yield 204 mg of a white solid (86.33% yield).
[0148] (3) Synthesis of compound Z15-C
[0149] Place 204 mg (741.11 μmol) of compound Z15-B in a two-necked flask under nitrogen. Pour 2 mL of redistilled DCM into the flask, add one drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0150] (4) Synthesis of compound Z15
[0151] Piperidine (741.11 μmol) was dissolved in redistilled DCM, and Et3N (1.48 mmol) was added. The mixture was stirred in an ice bath. Compound Z11-C was then diluted with DCM and added dropwise to the reaction mixture. After completion of the reaction, the mixture was evaporated under reduced pressure and purified by column chromatography (PE:EA = 2:1) to afford 170 mg of a white solid, with a yield of 57.28%. The product's NMR data are as follows: 1 H NMR (300MHz, CDCl3) δ7.29–7.17(m,4H),7.11(d,J=10.6Hz,2H),6.86(s,1H),5.15(d,J=8.7Hz,2H),3.85–3.74(m,3H),3.70(s,2H),3.35 (s, 2H), 2.30 (d, J = 7.8Hz, 6H), 1.65 (d, J = 14.0Hz, 6H).
[0152] Example 16
[0153] This example provides a method for synthesizing compound Z16, which is as follows: The method for synthesizing compound Z16 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by piperidine. The NMR data of the product are as follows: 1 H NMR (300MHz, CDCl3) δ7.37-7.16 (m, 6H), 7.01 (s, 1H), 5.15 (d, J = 4.4Hz, 2H), 3.70 (d ,J=5.9Hz,2H),3.35(t,J=5.2Hz,2H),2.29(d,J=4.4Hz,6H),1.65(d,J=18.4Hz,6H).
[0154] Example 17
[0155] Taking compound Z17 as an example, the specific preparation method is as follows. The reaction conditions are: (a) K2CO3, acetonitrile, 3-methylbenzyl bromide; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N2, rt; (d) piperidine, Et3N, DCM, 0°C.
[0156] (1) Synthesis of compound Z17-A
[0157] Compound Z1-D (Z1D, 500 mg, 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask. 30 mL of acetonitrile was added and stirred in an ice bath. 3-Methylbenzyl bromide was slowly added dropwise. After completion of the reaction, the product was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to yield 538 mg of a white solid in a 75.25% yield.
[0158] (2) Synthesis of compound Z17-B
[0159] Dissolve 538 mg (1.55 mmol) of compound Z17-A in 10 mL of glacial acetic acid, heat with stirring, raise the temperature to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction, evaporate the acetic acid under reduced pressure. Wash the remaining solid once with water and dissolve it in diethyl ether with stirring until a white solid precipitates. Collect the solid by filtration to obtain 400 mg of a white solid, with a yield of 70.48%.
[0160] (3) Synthesis of compound Z17-C
[0161] Place 200 mg (547.42 μmol) of compound Z17-B in a two-necked flask under nitrogen. Pour 2 mL of redistilled DCM into the flask, add one drop of anhydrous DMF, and stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and inject into the flask. After the reaction is complete, evaporate under reduced pressure.
[0162] (4) Synthesis of compound Z17
[0163] The synthesis method of compound Z17 refers to the synthesis method of Z1, except that 3-piperidinecarboxamide is replaced by piperidine, and Z1-G is replaced by Z17-C. The NMR data of the product are: 1 H NMR (500MHz, CDCl3) δ7.59 (dd, J=7.9, 2.2Hz, 1H), 7.41 (d, J=2.1Hz, 1H), 7.17 (dt, J=8.1, 1.0Hz, 3H), 7.11 (dq, J=7.2, 0.8Hz, 2H), 5.06 (t, J=1.0Hz,2H),3.63–3.56(m,1H),3.60–3.53(m,1H),3.53–3.45(m,2H),2.34(s,2H),2.28(d,J=1.1Hz,3H),2.23(s,2H),1.78–1.67(m,6H).
[0164] Example 18
[0165] This example provides a method for synthesizing compound Z18, as follows: The method for synthesizing compound Z18 is similar to that for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced with 4,4-difluoropiperidine. The NMR data of the product are as follows: 1H NMR (400MHz, CDCl3) δ7.57–7.51(m,2H),7.33(dd,J=5.0,2.0Hz,3H),7.22–7.20(m,1H),7.18(dd,J=7.8, 5.6Hz,2H),5.17(s,2H),3.92–3.81(m,2H),3.50(dd,J=6.9,4.8Hz,2H),2.29(s,6H),2.15–1.98(m,4H).
[0166] Example 19
[0167] This example provides a method for synthesizing compound Z19, which is as follows: The method for synthesizing compound Z19 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by piperidine. 1 H NMR (300MHz, CDCl3) δ7.58 (qd, J=3.6, 2.0Hz, 2H), 7.40–7.26 (m, 4H), 7.22 (d, J=1.7Hz, 2H), 5.1 9(d,J=1.5Hz,2H),3.73(d,J=5.4Hz,2H),3.37(t,J=5.3Hz,2H),2.31(s,6H),1.79–1.62(m,6H).
[0168] Example 20
[0169] This example provides a method for synthesizing compound Z20, which is as follows: The method for synthesizing compound Z20 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by morpholine. 1 H NMR (300MHz, CDCl3) δ7.54(d,J=5.7Hz,2H),7.32(dd,J=4.9,2.4Hz,2H),7.26(t,J=2.8Hz,2H),7.19(d,J=2.6Hz ,2H),5.20–5.13(m,2H),3.78(d,J=2.6Hz,4H),3.70(d,J=5.2Hz,2H),3.48–3.38(m,2H),2.29(t,J=2.7Hz,6H).
[0170] Example 21
[0171] This example provides a method for synthesizing compound Z21, as follows: The method for synthesizing compound Z21 is similar to that for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced with N-methyl-3-piperidinecarboxamide. The NMR data of the product are as follows: 1H NMR (300MHz, CDCl3) δ7.52 (dq, J=5.6, 3.1, 2.2Hz, 2H), 7.31 (dd, J=4.8, 2.6Hz, 3H), 7.25–7.14 (m, 3H), 6.03 (d, J=5.7Hz, 1H),5.15(d,J=4.7Hz,2H),4.59(d,J=13.4Hz,1H),4.38(dd,J=13.8,3.9Hz,1H),3.66(d,J=13.4Hz ,1H),3.51(d,J=13.4Hz,1H),3.38–2.66(m,6H),2.49–2.36(m,1H),2.28(s,6H),2.08–1.74(m,3H).
[0172] Example 22
[0173] This example provides a method for synthesizing compound Z22, as follows: The method for synthesizing compound Z22 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced with N,N-dimethyl 3-piperidinecarboxamide. The NMR data of the product are as follows: 1 H NMR (300MHz, CDCl3) δ7.52(ddd,J=15.1,6.7,3.2Hz,2H),7.40–7.29(m,3H),7.25–7.14(m,3H),5.16(q,J=7.3,6.1Hz,2H),4.72(d,J=12.7Hz ,1H),3.59(t,J=14.0Hz,1H),3.40(dd,J=13.8,10.8Hz,1H),3.24–3.07(m,2H),3.03–2.68(m,7H),2.29(d,J=4.9Hz,6H),2.08–1.64(m,5H).
[0174] Example 23
[0175] This example provides a method for synthesizing compound Z23, as follows, wherein the reaction conditions are (a) K2CO3, acetonitrile, 3-trifluoromethylbenzyl bromide; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N2, rt; and (d) ethyl 3-piperidinate, Et3N, DCM, 0°C.
[0176] (1) Synthesis of compound Z23-A
[0177] Z1-D (Z1D, 600 mg 2.48 mmol), 651.27 mg (2.72 mmol) of m-trifluoromethylbenzyl bromide, and 684.64 mg of potassium carbonate were placed in acetonitrile and stirred for 4 h. The mixture was extracted with DCM / H2O and recrystallized to obtain 670 mg of a white solid with a yield of 67.56%. 1 H NMR (400MHz, CDCl3) δ7.79(d,J=2.3Hz,1H),7.74(d,J=7.7Hz,1H),7.61(d,J=7.8Hz, 1H),7.48(t,J=7.8Hz,1H),7.24(s,1H),7.22–7.15(m,2H),5.21(s,2H),2.31(s,6H).
[0178] (2) Synthesis of compound Z23-B
[0179] Z23-A (1.24 mmol) was dissolved in 20 mL of acetic acid, and 4 mL of concentrated hydrochloric acid was added. The mixture was refluxed at 100°C for 4 h. After the reaction was completed, the acetic acid was evaporated under reduced pressure, and ether was added and stirred. After all the solids were precipitated, the mixture was filtered.
[0180] (3) Synthesis of compound Z23-C
[0181] Compound Z23-B (100 mg) was dissolved in dichloromethane, and DMF and oxalyl chloride (60.35 mg) were added, followed by stirring at room temperature, evaporation under reduced pressure, and the mixture was directly carried out to the next step.
[0182] (4) Synthesis of compound Z23
[0183] The synthesis method of compound Z23 refers to the synthesis method of Z1, except that 3-piperidinecarboxamide is replaced by Z23-C. NMR data of the product: 1 H NMR (300MHz, DMSO-d6) δ7.85–7.69(m,2H),7.57(d,J=7.8Hz,1H),7.45(t,J=7.7Hz,1H),7.22(d,J=12.2Hz,3H),5.08(t,J=1.0H z,2H),3.63–3.56(m,1H),3.57(dt,J=4.5,1.7Hz,1H),3.53–3.44(m,2H),2.28(d,J=1.1Hz,3H),2.23(s,2H),1.78–1.67(m,6H).
[0184] Example 24
[0185] This example provides a method for synthesizing compound Z24, as follows: The method for synthesizing compound Z24 is similar to that for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced with piperazine-1-carboxylic acid dimethylamine. The product NMR data are as follows: 1 H NMR (300MHz, CDCl3) δ7.31(t,J=5.8Hz,2H),7.28–7.16(m,4H),7.03(dd,J=9.4,5.7Hz,1H),5.31(s,1H),5. 16(s,2H),3.79(t,J=4.9Hz,2H),3.53–3.41(m,2H),3.32(dt,J=14.3,5.0Hz,4H),2.87(s,6H),2.30(s,6H).
[0186] Example 25
[0187] This example provides a method for synthesizing compound Z25, as follows: The method for synthesizing compound Z25 is similar to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced with ethyl N-piperazinecarboxylate. The product NMR data is as follows: 1 H NMR(300MHz,Deuterium Oxide)δ7.36–7.26(m,3H),7.20(dd,J=7.7,4.7Hz,3H),7.08–6.96(m,1H),4.17(q,J=7.1Hz,2H),3. 84–3.69(m,2H),3.63–3.48(m,4H),3.40(dd,J=6.7,3.5Hz,2H),2.29(s,6H),1.27(t,J=7.0Hz,3H).
[0188] Example 26
[0189] This example provides a method for synthesizing compound Z26, as follows: The method for synthesizing compound Z26 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced with tert-butyl 1,4-diazepane-1-carboxylate. The product NMR data is as follows: 1H NMR(300MHz,Deuterium Oxide)δ7.36–7.26(m,3H),7.20(dd,J=7.7,4.7Hz,3H),7.08–6.96(m,1H),4.17(q,J=7.1Hz,2H),3. 84–3.69(m,2H),3.63–3.48(m,4H),3.40(dd,J=6.7,3.5Hz,2H),2.29(s,6H),1.27(t,J=7.0Hz,3H).
[0190] Example 27
[0191] This example provides a method for synthesizing compound Z27, as follows: The method for synthesizing compound Z27 is similar to that for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced with 1-tert-butyloxycarbonylpiperazine. The NMR data of the product are as follows: 1 H NMR (300MHz, CDCl3) δ7.31 (s, 2H), 7.26–7.14 (m, 4H), 7.00 (d, J = 9.4Hz, 1H), 5. 14(s,2H),3.74(t,J=5.2Hz,2H),3.57–3.34(m,6H),2.29(s,6H),1.47(s,9H).
[0192] Example 28
[0193] This example provides a method for synthesizing compound Z28, as follows: The method for synthesizing compound Z28 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced with 4,4-difluoropiperidine. The NMR data of the product are as follows: 1 H NMR (300MHz, CDCl3) δ-9.56–-9.81(m,6H),-9.88–-10.00(m,1H),-11.79(d,J=3.5Hz,2H),-13.04–-13. 17(m,2H),-13.42(dt,J=7.3,4.0Hz,2H),-14.64(d,J=3.4Hz,6H),-14.88(dq,J=16.0,9.3,8.0Hz,4H).
[0194] Example 29
[0195] This example provides a method for synthesizing compound Z29, as follows: The method for synthesizing compound Z29 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced with tert-butyl tetrahydropyrimidine-1(2H)-carboxylate. The product NMR data are as follows: 1H NMR (300MHz, CDCl3) δ7.32(d,J=6.2Hz,2H),7.22(d,J=6.4Hz,3H),7.02(d,J=8.5Hz,1H),5.15(s,2H), 4.93(s,2H),3.87(t,J=5.8Hz,2H),3.61(t,J=5.7Hz,2H),2.35–2.27(m,6H),1.76(s,2H),1.44(s,9H).
[0196] Example 30
[0197] This embodiment provides a method for synthesizing compound Z30, which is as follows: The method for synthesizing compound Z30 refers to the method for synthesizing Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by (S)-3-Boc-aminopiperidine. 1 H NMR (300MHz, CDCl3) δ7.32(d,J=11.0Hz,4H),7.25(d,J=10.2Hz,3H),7.04(s,1H),5.18(s,2H),4.90(d,J=35.2Hz, 1H), 3.93–3.36 (m, 2H), 3.36–3.10 (m, 1H), 2.31 (d, J = 2.9Hz, 6H), 1.87 (d, J = 27.4Hz, 4H), 1.49 (s, 3H), 1.41 (s, 6H).
[0198] Example 31
[0199] This embodiment provides a method for synthesizing compound Z31, which is as follows: The method for synthesizing compound Z31 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by (R)-3-Boc-aminopiperidine. 1 H NMR (300MHz, CDCl3) δ7.32(d,J=11.0Hz,4H),7.25(d,J=10.2Hz,3H),7.04(s,1H),5.18(s,2H),4.90(d,J=35.2Hz, 1H), 3.93–3.36 (m, 2H), 3.36–3.10 (m, 1H), 2.31 (d, J = 2.9Hz, 6H), 1.87 (d, J = 27.4Hz, 4H), 1.49 (s, 3H), 1.41 (s, 6H).
[0200] Example 32
[0201] This embodiment provides a method for preparing compound Z32, as follows: The synthesis method of compound Z32 refers to the synthesis method of Z12, except that N-(propyl-2-alkyn-1-yl)piperidine-3-carboxamide is replaced by 1-cyclopropylcarbonylpiperazine. 1 H NMR(300MHz, CDCl3)δ7.30(dd,J=11.9,3.5Hz,3H),7.25–7.16(m,3H),7.03(t,J=8.6Hz,1H),5.16(s,2H),3 .76(d,J=25.2Hz,6H),3.45(s,2H),2.31(s,6H),1.74(s,1H),1.02(q,J=4.0Hz,2H),0.83(d,J=7.5Hz,2H).
[0202] Example 33
[0203] This example provides a method for synthesizing compound Z33, as follows: The synthesis method for compound Z33 refers to the synthesis method for Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced with morpholine (237.17 μmol) and dissolved in redistilled DCM. Et3N (434.19 μmol) is added and stirred in an ice bath. Intermediate 22 is then diluted with DCM and added dropwise to the reaction solution. After completion of the reaction, the mixture is evaporated under reduced pressure and purified by column chromatography (PE:EA = 2:1) to obtain 102 mg of a white solid with a yield of 65.12%. The NMR data of the product are as follows: 1 H NMR (300MHz, CDCl3) δ7.30 (s, 2H), 7.23 (s, 4H), 7.00 (t, J = 8.2Hz, 1H), 5.14 (s, 2H), 3.74–3.66 (m, 6H), 3.63 (dd, J = 6.3, 3.5Hz, 2H), 2.28 (s, 6H).
[0204] Example 34
[0205] This example provides a method for synthesizing compound Z34, as follows: The method for synthesizing compound Z34 is similar to that for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced with tert-butyl 3,8-diazabicyclo[3.2.1]octane-3-carboxylate. The NMR data of the product are as follows: 1H NMR (300MHz, CDCl3) δ7.31(s,2H),7.19(d,J=11.3Hz,4H),7.00(d,J=8.8Hz,1H),5.14(s,2H),4.80(s,1H), 4.07–3.77(m,3H),3.11(dd,J=31.5,15.1Hz,2H),2.29(s,6H),2.00(s,2H),1.87–1.73(m,2H),1.45(s,9H).
[0206] Example 35
[0207] This embodiment provides a method for synthesizing compound Z35, which is as follows: The method for synthesizing compound Z35 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced by 3-N-tert-butoxycarbonylaminocyclobutylamine. 1 H NMR (300MHz, CDCl3) δ7.30 (d, J=5.6Hz, 2H), 7.26–7.13 (m, 4H), 7.00 (td, J=7.9, 6.6, 2.2Hz, 1H), 5.1 2(s,3H),4.48(d,J=10.5Hz,3H),4.14–4.03(m,1H),3.99(d,J=7.7Hz,1H),2.30(s,6H),1.37(s,9H).
[0208] Example 36
[0209] This example provides a method for synthesizing compound Z36, as follows: The method for synthesizing compound Z36 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced with tert-butyl azetidin-3-yl(methyl)carbamate. Product NMR data: 1 H NMR (300MHz, CDCl3) δ7.39–7.28(m,3H),7.20(d,J=12.2Hz,3H),7.02(t,J=8.3Hz,1H),5.15(s,2H) ,4.39–4.31(m,2H),4.26(dd,J=14.4,6.0Hz,2H),2.92(d,J=1.7Hz,3H),2.31(s,6H),1.46(s,9H).
[0210] Example 37
[0211] This example provides a method for synthesizing compound Z37, as follows: The method for synthesizing compound Z37 refers to the method for synthesizing compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide is replaced with 3-Boc-aminomethylpiperidine. The product NMR data: 1 H NMR (300MHz, CDCl3) δ7.33–7.24(m,3H),7.23–7.17(m,3H),7.02(d,J=8.3Hz,1H),5.1 4(s,2H),4.84(s,0.5H),4.53(s,0.5H),4.37(d,J=13.2Hz,0.5H),4.13(d,J=13.2Hz,0 .5H),3.58–3.41(m,1H),3.20(d,J=9.2Hz,1H),3.04(dt,J=23.6,9.0Hz,3H),2.29(s, 6H), 1.79 (d, J = 19.1Hz, 3H), 1.58 (s, 1H), 1.44 (s, 6H), 1.37 (s, 3H), 1.29–1.16 (m, 1H).
[0212] Example 38
[0213] This example provides a method for synthesizing compound Z38, as follows: The method for synthesizing compound Z38 is the same as that for Z15, except that piperidine is replaced with 3-Boc-aminomethylpiperidine. The NMR data of the product are as follows: 1 H NMR (300MHz, CDCl3) δ7.29–7.17(m,4H),7.11(d,J=10.6Hz,2H),6.86(s,1H),5.15(d,J=8.7Hz,2H)4.37(d,J=13.2Hz,0.5H),4.13(d,J=13.2Hz, 0.5H),3.85–3.74(m,3H),3.58–3.41(m,1H),3.20(d,J=9.2Hz,1H),3.04(dt,J=23.6,9.0Hz,3H) ,2.29(s,6H),1.79(d,J=19.1Hz,3H),1.58(s,1H),1.44(s,6H),1.37(s,3H),1.29–1.16(m,1H).
[0214] Example 39
[0215] This example provides a method for synthesizing compound Z39, as follows: The synthesis of compound Z39 is the same as compound Z17, except that piperidine is replaced with 3-Boc-aminomethylpiperidine. Product NMR data: 1H NMR (500MHz, CDCl3) δ7.59 (dd, J=7.9, 2.2Hz, 1H), 7.41 (d, J=2.2Hz, 1H), 7.28 (ddq, J=7.9, 2.2, 1.1Hz, 1H), 7.21–7.14(m,2H),7.12(t,J=2.1Hz,1H),7.13–7.04(m,1H),5.09–4.99(m,2H),4.91(t,J=6.3Hz,1H),3.73( dd,J=12.5,4.8Hz,1H),3.61–3.48(m,2H),3.47(dd,J=12.5,4.8Hz,1H),3.17–3.08(m,2H),2.32(d,J=0.7Hz ,3H),2.28(d,J=1.1Hz,3H),2.25(tt,J=6.2,4.9Hz,1H),1.76–1.59(m,3H),1.50–1.41(m,1H),1.42(s,7H).
[0216] Example 40
[0217] This example provides a method for synthesizing compound Z40, as follows: The synthesis of compound Z40 was based on compound Z12, except that N-propyl-2-yn-1-ylpiperidine-3-carboxamide was replaced with N-(oct-7-yn-1-yl)piperidine-3-carboxamide. The product NMR data are as follows: 1 H NMR (300MHz, CDCl3) δ7.27(dt,J=11.8,5.5Hz,6H),7.01(d,J=8.2Hz,1H),6.62(t,J=5.1Hz,1H),5.14(s,2H),4.72(dd ,J=13.4,4.1Hz,0.5H),4.42–4.34(m,0.5H),4.16–3.97(m,2H),3.74(dd,J=13.8,4.1Hz,0.5H),3.57(d,J=13.5Hz,0. 5H),3.37(dd,J=13.7,10.0Hz,0.5H),3.18–2.96(m,1.5H),2.63(tt,J=11.0,5.1Hz,1H),2.29(s,6H),2.24–2.09(m,3 H), 1.95 (d, J = 2.6Hz, 1H), 1.87–1.71 (m, 2H), 1.64 (td, J = 13.0, 12.3, 6.2Hz, 4H), 1.37 (tdd, J = 24.5, 14.9, 7.8Hz, 5H).
[0218] Example 41
[0219] This example provides a method for synthesizing compound Z41, which is as follows: The synthesis of compound Z41 refers to compound Z1, except that 3-piperidinecarboxamide is replaced by azetidine. 1 H NMR (300MHz, CDCl3) δ7.56 (dd, J=6.3, 3.0Hz, 2H), 7.44–7.28 (m, 3H), 7.25–7.10 (m, 3H), 5.16 (s, 2H), 4.22 (q, J = 8.2Hz, 4H), 2.34 (d, J = 8.7Hz, 2H), 2.29 (s, 6H).
[0220] Example 42
[0221] This example provides a method for synthesizing compound Z42, as follows: The method for synthesizing compound Z42 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced with N,N-dimethylethylenediamine. The product NMR data: 1 H NMR(300MHz, CDCl3)δ8.80(s,1H),7.65–7.15(m,9H),5.20(s,2H),3.57(q,J=6 .0Hz, 2H), 2.55 (t, J = 6.2Hz, 2H), 2.30 (d, J = 8.9Hz, 12H), 1.27 (d, J = 8.9Hz, 2H).
[0222] Example 43
[0223] This example provides a method for synthesizing compound Z43, which is as follows: The method for synthesizing compound Z43 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by N-(2-aminoethyl)morpholine. 1 HNMR(300MHz, CDCl3)δ8.97(s,1H),7.54(s,2H),7.34(s,4H),7.22(s,2H),5.21( s,2H),3.75(s,4H),3.57(s,2H),2.59(s,2H),2.52(s,4H),2.29(d,J=5.0Hz,6H).
[0224] Example 44
[0225] This example provides a method for synthesizing compound Z44, as follows: The method for synthesizing compound Z44 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by 2-pyridinemethylamine. The product NMR data: 1H NMR(300MHz, CDCl3)δ9.52(s,1H),8.61(s,1H),7.67(s,1H),7.54(s,2H),7.33 (s, 4H), 7.21 (s, 4H), 5.21 (d, J = 4.2Hz, 2H), 4.79 (s, 2H), 2.28 (d, J = 4.1Hz, 6H).
[0226] Example 45
[0227] This example provides a method for synthesizing compound Z45, as follows: The method for synthesizing compound Z45 refers to the method for synthesizing compound Z1, except that 3-piperidinecarboxamide is replaced by tetrahydropyrrole. The NMR data of the product are as follows: 1 H NMR (400MHz, CDCl3) δ7.62–7.52(m,2H),7.32(dd,J=5.1,2.0Hz,3H),7.22(d,J=1.9Hz,1H),7.20–7.1 6(m,2H),5.17(s,2H),3.69–3.59(m,2H),3.49–3.41(m,2H),2.28(d,J=1.7Hz,6H),2.00–1.90(m,4H).
[0228] Example 46
[0229] This example provides a method for synthesizing compound Z46, as follows: The synthesis of compound Z46 was based on compound Z12, except that N-(propyl-2-yn-1-yl)piperidine-3-carboxamide was replaced with 3-(methylsulfonyl)piperidine. The product NMR data are as follows: 1 H NMR (500MHz, CDCl3) δ7.59 (dd, J=7.9,2.2Hz,1H),7.41(d,J=2.2Hz,1H),7.34(td,J=8.0,5.0Hz,1H),7.17(dq,J=8.0,1.0Hz, 1H),7.12(dddd,J=8.2,4.2,2.0,1.0Hz,3H),7.03(tdd,J=7.9,2.0,1.2Hz,1H),5.06(d,J=1.8 Hz,2H),4.00(dd,J=12.3,6.9Hz,1H),3.88(dd,J=12.4,6.9Hz,1H),3.62–3.55(m,1H),3.58–3 .49(m,3H),2.99(d,J=1.5Hz,4H),2.28(d,J=1.1Hz,3H),2.23(s,3H),2.09–1.97(m,2H),1.92–
[0230] 1.68 (m, 4H).
[0231] Example 47
[0232] This example provides a method for synthesizing compound Z47, as detailed below. The reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile; (d) HCl, AcOH, 110°C; (e) oxalyl chloride, DMF, DCM, N2; and (f) piperidine, Et3N, DCM, 0°C.
[0233] (1) Synthesis of compound Z47B
[0234] The synthesis of compound Z47B refers to compound Z1C, except that compound Z1A is replaced by compound Z47A. NMR data of the product: 1 H NMR (500MHz, CDCl3) δ9.24(s,1H),8.28(dd,J=4.3,1.6Hz,1H),7.67(td,J=7.0,1.7Hz,1H),7.30(dd ,J=7.0,1.5Hz,1H),6.93(ddd,J=7.0,4.2,1.5Hz,1H),4.21(q,J=6.4Hz,2H),1.27(t,J=6.2Hz,3H).
[0235] (2) Synthesis of compound Z47C
[0236] The synthesis of compound Z47C was based on compound Z1D, except that compound Z1C was replaced by compound Z47B.
[0237] (3) Synthesis of compound Z47D
[0238] The synthesis of compound Z47D refers to compound Z1E, except that compound Z1D is replaced by compound Z47-C. NMR data of the product: 1 H NMR (500MHz, CDCl3) δ8.41 (dd, J = 4.5, 1.7 Hz, 1H), 7.72 (dd, J = 6.5, 1.5 Hz, 1H), 7.64–7.58 (m, 1H), 7.33–7.21 (m, 6H), 5.08 (d, J = 1.0 Hz, 2H).
[0239] (4) Synthesis of compound Z47E
[0240] The synthesis of compound Z47E was based on compound Z1F, except that compound Z1E was replaced by compound Z47-D.
[0241] (5) Synthesis of compound Z47F
[0242] The synthesis of compound Z47F was based on compound Z1G, except that compound Z1F was replaced by compound Z47E.
[0243] (6) Synthesis of compound Z47
[0244] The synthesis of compound Z47 was based on compound Z1, except that compound Z1G was replaced by compound Z47F. 1 H NMR (500MHz, CDCl3) δ8.41(dd,J=4.5,1.7Hz,1H),7.72(dd,J=6.5,1.3Hz,1H),7.61(ddd,J=7.3,6.5,1.7Hz,1H),7.39–7.21(m,6H),5.05(q, J=0.9Hz,2H),3.80(dd,J=12.4,5.6Hz,1H),3.68(dd,J=12.4,5.6Hz,1H),3.64–3.54(m,2H),2.60(tt,J=6.9,5.6Hz,1H),1.94–1.62(m,4H).
[0245] Example 48
[0246] This example provides a method for synthesizing compound Z48, as detailed below. Reaction conditions: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile; (d) HCl, AcOH, 110°C; (e) oxalyl chloride, DMF, DCM, N2; (f) piperidine, Et3N, DCM, 0°C.
[0247] (1) Synthesis of compound Z48B
[0248] The synthesis of compound Z48B refers to compound Z1C, except that compound Z1B is replaced by compound Z48A. 1 H NMR(500MHz,CDCl3)δ9.23(s,1H),7.92(d,J=7.6Hz,1H),7.85–7.80(m,2H),7.74(dt,J=7.4,1.9Hz ,1H),7.50–7.44(m,2H),7.37(dd,J=7.7,2.2Hz,1H),4.21(q,J=6.3Hz,2H),1.27(t,J=6.2Hz,3H).
[0249] (2) Synthesis of compound Z48C
[0250] The synthesis of compound Z48C was based on compound Z1D, except that compound Z1C was replaced by compound Z48-B.
[0251] (3) Synthesis of compound Z48D
[0252] The synthesis of compound Z48D refers to compound Z1E, except that compound Z1D is replaced by compound Z48C. NMR data of the product: 1 H NMR(500MHz, CDCl3)δ8.12(t,J=2.0Hz,1H),7.99(d,J=7.2Hz,1H),7.93–7.80(m,2H),7 .72(dd,J=7.2,2.3Hz,1H),7.55–7.41(m,2H),7.36–7.23(m,5H),5.08(d,J=1.1Hz,2H).
[0253] (4) Synthesis of compound Z48E
[0254] The synthesis of compound Z48E was based on compound Z1F, except that compound Z1E was replaced by compound Z48D.
[0255] (5) Synthesis of compound Z48F
[0256] The synthesis of compound Z48F was based on compound Z1G, except that compound Z1F was replaced by compound Z48E.
[0257] (6) Synthesis of compound Z48
[0258] The synthesis of compound Z48 was based on compound Z1, except that compound Z1G was replaced by compound Z48F. 1 H NMR (500MHz, CDCl3) δ8.12(t,J=2.1Hz,1H),7.99(d,J=7.2Hz,1H),7.92–7.80(m,2H),7.72(dd,J=7.2,2.3Hz,1H),7.51–7.43(m,2H),7.34–7.23 (m,5H),5.20–4.97(m,2H),3.80(dd,J=12.4,5.6Hz,1H),3.68(dd,J=12 .4,5.6Hz,1H),3.64–3.56(m,2H),2.65–2.51(m,1H),1.95–1.65(m,4H).
[0259] Example 49
[0260] This example provides a method for synthesizing compound Z49, as shown below. The reaction conditions are: (a) K2CO3, acetonitrile, 2-bromomethylpyridine; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N2, rt; (d) piperidine, Et3N, DCM, 0°C.
[0261] (1) Synthesis of Compound Z49-A: Compound Z1-D (500 mg, 2.06 mmol) and potassium carbonate (458.39 mg, 2.48 mmol) were placed in a 100 mL round-bottom flask. Acetonitrile (30 mL) was added and stirred in an ice bath. 2-Bromomethylpyridine was slowly added dropwise. After the reaction, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to obtain 538 mg of a white solid (75.25% yield).
[0262] (2) Synthesis of Compound Z49-B: 538 mg (1.55 mmol) of Compound Z49-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0263] (3) Synthesis of Compound Z49-C: Place 200 mg (547.42 μmol) of Compound Z49-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add a drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0264] (4) Synthesis of compound Z49: The synthesis method of compound Z49 refers to the synthesis method of Z1, except that Z1G is replaced by Z49-C. NMR data of the product: 1H NMR (500MHz, CDCl3) δ8.49 (dd, J=4.1, 1.7Hz, 1H), 7.74 (td, J=7.6, 1.7Hz, 1H), 7.59 (dd, J=7.9, 2 .2Hz,1H),7.52(ddd,J=7.5,4.2,1.5Hz,1H),7.41(d,J=2.1Hz,1H),7.34(dd,J=7.8,1.4Hz,1H), 7.17(dq,J=8.0,1.1Hz,1H),5.01–4.77(m,2H),3.80(dd,J=12.4,5.6Hz,1H),3.68(dd,J=12.4,5 .6Hz,1H),3.65–3.53(m,2H),3.26(tt,J=6.9,5.6Hz,1H),2.32–2.21(m,6H),1.94–1.66(m,4H).
[0265] Example 50
[0266] This example provides a method for synthesizing compound Z50, as detailed below. The reaction conditions are: (a) NaNO₂, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K₂CO₃, acetonitrile; (d) HCl, AcOH, 110°C; (e) oxalyl chloride, DMF, DCM, N₂; and (f) piperidine, Et₃N, DCM, 0°C.
[0267] (1) Synthesis of compound Z50B: The synthesis of compound Z50B was based on the same method as compound Z1C, except that compound Z1A was replaced by compound Z50A.
[0268] (2) Synthesis of compound Z50C: The synthesis of compound Z50C was based on the method of compound Z1D, except that compound Z1C was replaced by compound Z50B.
[0269] (3) Synthesis of compound Z50D: The synthesis of compound Z50D was based on compound Z1E, except that compound Z1D was replaced by compound Z50C.
[0270] (4) Synthesis of compound Z50E: The synthesis of compound Z50E was based on compound Z1F, except that compound Z1E was replaced by compound Z50D.
[0271] (5) Synthesis of compound Z50F: The synthesis of compound Z50F was based on compound Z1G, except that compound Z1F was replaced by compound Z50E.
[0272] (6) Synthesis of Compound Z50: The synthesis of Compound Z50 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z50F. 1 H NMR (500MHz, CDCl3) δ7.76–7.65(m,4H),7.63–7.56(m,2H),7.48–7.41(m,2H),7.41–7.34(m,1H),7.34–7.23(m,5H),5.14–5.03(m,2H),3.80 (dd,J=12.4,5.6Hz,1H),3.68(dd,J=12.4,5.6Hz,1H),3.65–3.53(m,2H),2.60(tt,J=6.9,5.6Hz,1H),1.93–1.79(m,2H),1.83–1.66(m,2H).
[0273] Example 51
[0274] This example provides a method for synthesizing compound Z51, as detailed below. The reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile; (d) HCl, AcOH, 110°C; (e) oxalyl chloride, DMF, DCM, N2; and (f) Et3N, DCM, 0°C.
[0275] (1) Synthesis of compound Z51B: The synthesis of compound Z51B was based on the method of compound Z1C, except that compound Z1A was replaced by compound Z51A.
[0276] (2) Synthesis of compound Z51C: The synthesis of compound Z51C was based on compound Z1D, except that compound Z1C was replaced by compound Z51B.
[0277] (3) Synthesis of compound Z51D: The synthesis of compound Z51D was based on compound Z1E, except that compound Z1D was replaced by compound Z51C.
[0278] (4) Synthesis of compound Z51E: The synthesis of compound Z51E was based on compound Z1F, except that compound Z1E was replaced by compound Z51D.
[0279] (5) Synthesis of compound Z51F: The synthesis of compound Z51F was based on compound Z1G, except that compound Z1F was replaced by compound Z51E.
[0280] (6) Synthesis of compound Z51: The synthesis of compound Z51 was based on the same method as compound Z1, except that compound Z1G was replaced by compound Z51F. 1 H NMR (500MHz, CDCl3) δ7.73–7.63(m,4H),7.32–7.24(m,5H),5.13–5.05(m,2H),3.80(dd,J=12.4,5.6Hz,1H), 3.68(dd,J=12.4,5.6Hz,1H),3.65–3.54(m,2H),3.18(s,3H),2.60(tt,J=6.9,5.6Hz,1H),1.98–1.63(m,4H).
[0281] Example 52
[0282] This example provides a method for synthesizing compound Z52, as detailed below. The reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile; (d) HCl, AcOH, 110°C; (e) oxalyl chloride, DMF, DCM, N2; and (f) piperidine, Et3N, DCM, 0°C.
[0283] (1) Synthesis of compound Z52B: The synthesis of compound Z52B was based on the method of compound Z1C, except that compound Z1A was replaced by compound Z52A.
[0284] (2) Synthesis of compound Z52C: The synthesis of compound Z52C was based on compound Z1D, except that compound Z1C was replaced by compound Z52B.
[0285] (3) Synthesis of compound Z52D: The synthesis of compound Z52D was based on compound Z1E, except that compound Z1D was replaced by compound Z52C.
[0286] (4) Synthesis of compound Z52E: The synthesis of compound Z52E was based on compound Z1F, except that compound Z1E was replaced by compound Z52D.
[0287] (5) Synthesis of compound Z52F: The synthesis of compound Z52F was based on compound Z1G, except that compound Z1F was replaced by compound Z52E.
[0288] (6) Synthesis of Compound Z52: The synthesis of Compound Z52 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z52F. The NMR data of the product were: 1H NMR (500MHz, CDCl3) δ7.70–7.62(m,2H),7.34–7.23(m,5H),7.17–7.10(m,2H),5.14–5.03(m,2H),3.80(dd,J=12.4,5.6Hz,1H),3.6 8(dd,J=12.4,5.6Hz,1H),3.65–3.53(m,2H),2.60(tt,J=6.9,5.6Hz,1H),1.93–1.80(m,2H),1.83–1.73(m,1H),1.76–1.66(m,1H).
[0289] Example 53
[0290] This example provides a method for synthesizing compound Z53, as detailed below. The reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile; (d) HCl, AcOH, 110°C; (e) oxalyl chloride, DMF, DCM, N2; and (f) piperidine, Et3N, DCM, 0°C.
[0291] (1) Synthesis of compound Z53B: The synthesis of compound Z53B was based on the method of compound Z1C, except that compound Z1A was replaced by compound Z53A.
[0292] (2) Synthesis of compound Z53C: The synthesis of compound Z53C was based on compound Z1D, except that compound Z1C was replaced by compound Z53B.
[0293] (3) Synthesis of compound Z53D: The synthesis of compound Z53D was based on compound Z1E, except that compound Z1D was replaced by compound Z53C.
[0294] (4) Synthesis of compound Z53E: The synthesis of compound Z53E was based on the same method as compound Z1F, except that compound Z1E was replaced by compound Z53D.
[0295] (5) Synthesis of compound Z53F: The synthesis of compound Z53F was based on compound Z1G, except that compound Z1F was replaced by compound Z53E.
[0296] (6) Synthesis of compound Z53: The synthesis of compound Z53 was based on the same method as compound Z1, except that compound Z1G was replaced by compound Z53F. 1H NMR(500MHz, CDCl3)δ9.30(s,1H),7.69–7.62(m,2H),7.57–7.51(m,2H),7.34–7.23(m,5H),5.09(dt,J=2.9,0.9Hz,2H),3.80(dd,J=12.4,5 .6Hz,1H),3.68(dd,J=12.4,5.6Hz,1H),3.65–3.53(m,2H),2.60(tt,J=6.9,5.6Hz,1H),2.16(s,2H),1.93–1.80(m,2H),1.83–1.66(m,2H).
[0297] Example 54
[0298] This example provides a method for synthesizing compound Z54, as detailed below. The reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile; (d) HCl, AcOH, 110°C; (e) oxalyl chloride, DMF, DCM, N2; and (f) piperidine, Et3N, DCM, 0°C.
[0299] (1) Synthesis of compound Z54B: The synthesis of compound Z54B was based on the method of compound Z1C, except that compound Z1A was replaced by compound Z54A.
[0300] (2) Synthesis of compound Z54C: The synthesis of compound Z54C was based on compound Z1D, except that compound Z1C was replaced by compound Z54B.
[0301] (3) Synthesis of compound Z54D: The synthesis of compound Z54D was based on compound Z1E, except that compound Z1D was replaced by compound Z54C.
[0302] (4) Synthesis of compound Z54E: The synthesis of compound Z54E was carried out with reference to compound Z1F, except that compound Z1E was replaced by compound Z54D.
[0303] (5) Synthesis of compound Z54F: The synthesis of compound Z54F was based on compound Z1G, except that compound Z1F was replaced by compound Z54E.
[0304] (6) Synthesis of Compound Z54: The synthesis of Compound Z54 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z54F. 1H NMR (500MHz, CDCl3) δ7.69–7.63(m,2H),7.34–7.24(m,5H),7.27–7.19(m,2H),5.14–5.03(m,2H),3.80(dd,J=12.4,5.6Hz,1H),3.68(dd, J=12.4,5.6Hz,1H),3.65–3.53(m,2H),2.60(tt,J=6.9,5.6Hz,1H),2.28(s,2H),1.93–1.81(m,2H),1.84–1.73(m,1H),1.76–1.66(m,1H).
[0305] Example 55
[0306] This example provides a synthesis method for compound Z55, as shown below. The reaction conditions are: (a) K2CO3, acetonitrile, β-bromomethylnaphthalene; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N2, rt; and (d) piperidine, Et3N, DCM, 0°C.
[0307] (1) Synthesis of compound Z55-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, 30 mL of acetonitrile was added, and the mixture was stirred in an ice bath. β-bromomethylnaphthalene was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA=10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0308] (2) Synthesis of Compound Z55-B: 538 mg (1.55 mmol) of Compound Z55-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0309] (3) Synthesis of Compound Z55-C: Place 200 mg (547.42 μmol) of Compound Z55-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0310] (4) Synthesis of Compound Z55: The synthesis method of compound Z55 refers to the synthesis method of Z1, except that Z1G is replaced by Z55-C. NMR data of the product: 1 H NMR (500MHz, CDCl3) δ8.13–8.07(m,1H),7.86–7.78(m,2H),7.77–7.71(m,1H),7.59(dd,J=7. 9,2.2Hz,1H),7.55–7.43(m,2H),7.41(d,J=2.1Hz,1H),7.25(dd,J=8.5,2.2Hz,1H),7.17(dq ,J=8.0,1.1Hz,1H),5.12(s,2H),3.80(dd,J=12.4,5.6Hz,1H),3.68(dd,J=12.4,5.6Hz,1H), 3.65–3.53(m,2H),2.64–2.56(m,1H),2.28(d,J=1.1Hz,3H),2.23(s,2H),1.93–1.66(m,4H).
[0311] Example 56
[0312] This example provides a method for synthesizing compound Z56, as detailed below. The reaction conditions are: (a) K2CO3, acetonitrile, 1-bromomethyl-3-methylsulfonylbenzene; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N2, rt; and (d) piperidine, Et3N, DCM, 0°C.
[0313] (1) Synthesis of Compound Z56-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. 1-Bromomethyl-3-methylsulfonylbenzene was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0314] (2) Synthesis of Compound Z56-B: 538 mg (1.55 mmol) of Compound Z56-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0315] (3) Synthesis of Compound Z56-C: Place 200 mg (547.42 μmol) of Compound Z56-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add a drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0316] (4) Synthesis of Compound Z56: The synthesis method of compound Z56 refers to the synthesis method of Z1, except that Z1G is replaced by Z56-C. NMR data of the product: 1 H NMR (500MHz, CDCl3) δ7.80–7.72(m,2H),7.59(dd,J=7.9,2.2Hz,1H),7.46–7.37(m,3H),7.17(dq,J=8.0,1.1Hz,1H),5.06(d,J= 0.9Hz,2H),3.80(dd,J=12.4,5.6Hz,1H),3.68(dd,J=12.4,5.6Hz,1H),3.65–3.53(m,2H),3.18(s,2H),2.60(tt,J=6.9,5.6Hz, 1H), 2.28 (d, J = 1.1Hz, 3H), 1.93–1.80 (m, 2H), 1.83–1.73 (m, 1H), 1.76–1.66 (m, 1H).
[0317] Example 57
[0318] This example provides a method for synthesizing compound Z57, as detailed below. The reaction conditions are: (a) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N2, rt; and (d) piperidine, Et3N, DCM, 0°C.
[0319] (1) Synthesis of Compound Z57-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask. 30 mL of acetonitrile was added and stirred in an ice bath. 3-(bromomethyl)benzoic acid ethyl ester was added. After the reaction was completed, the product was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0320] (2) Synthesis of Compound Z57-B: Dissolve 538 mg (1.55 mmol) of compound Z57-A in 10 mL of glacial acetic acid, heat with stirring, raise the temperature to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction, evaporate the glacial acetic acid under reduced pressure. Wash the remaining solid once with water and dissolve it in ether with stirring until a white solid precipitates. Collect the solid by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0321] (3) Synthesis of Compound Z57-C: Place 200 mg (547.42 μmol) of Compound Z57-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0322] (4) Synthesis of Compound Z57: The synthesis method of compound Z57 refers to Z17, except that Z17-C is replaced by Z57-C. NMR data of the product: 1 H NMR (500MHz, CDCl3) δ7.87 (ddd, J=7.9, 2.4, 1.5Hz, 1H), 7.83 (tt, J=2.2, 1.0Hz, 1H), 7.59 (dd ,J=7.9,2.2Hz,1H),7.44–7.37(m,2H),7.39–7.33(m,1H),7.20–7.14(m,1H),5.15–5.04(m,2H ),4.35(q,J=6.4Hz,2H),3.80(dd,J=12.4,5.6Hz,1H),3.68(dd,J=12.4,5.6Hz,1H),3.65–3. 53(m,2H),2.65–2.56(m,1H),2.28(d,J=1.1Hz,3H),1.93–1.66(m,4H),1.38(t,J=6.4Hz,3H).
[0323] Example 58
[0324] This example provides a synthesis method for compound Z58, as detailed below. The reaction conditions are: (a) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N2, rt; and (d) piperidine, Et3N, DCM, 0°C.
[0325] (1) Synthesis of Compound Z58-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. 3-(bromomethyl)benzoic acid ethyl ester was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA=10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0326] (2) Synthesis of Compound Z58-B: 538 mg (1.55 mmol) of Compound Z58-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0327] (3) Synthesis of Compound Z58-C: Place 200 mg (547.42 μmol) of Compound Z58-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0328] (4) Synthesis of Compound Z58: The synthesis method of compound Z58 refers to the synthesis method of Z1, except that Z1G is replaced by Z58-C. NMR data of the product: 1 H NMR(500MHz, CDCl3)δ9.10(s,1H),7.59(dd,J=7.9,2.2Hz,1H),7.56–7.50(m,2H),7.41(d,J=2.2Hz, 1H),7.29–7.22(m,1H),7.17(dq,J=8.0,1.1Hz,1H),7.14–7.07(m,1H),5.12–5.01(m,2H),3.80(dd,J =12.4,5.6Hz,1H),3.68(dd,J=12.4,5.6Hz,1H),3.65–3.53(m,2H),2.60(tt,J=6.9,5.6Hz,1H),2.28 (d,J=1.1Hz,3H),2.23(s,2H),2.16(s,2H),1.93–1.81(m,2H),1.84–1.73(m,1H),1.76–1.66(m,1H).
[0329] Example 59
[0330] This example provides a method for synthesizing compound Z59, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0331] (1) Synthesis of Compound Z59-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask. 30 mL of acetonitrile was added and stirred in an ice bath. 2-Fluorobenzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0332] (2) Synthesis of Compound Z59-B: 538 mg (1.55 mmol) of compound Z59-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0333] (3) Synthesis of Compound Z59-C: Place 200 mg (547.42 μmol) of Compound Z59-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0334] (4) Synthesis of compound Z59: The synthesis method of compound Z59 refers to the synthesis method of Z1, except that Z1G is replaced by Z59-C. Product NMR data: 1 H NMR (300MHz, CDCl3) δ7.47(t,J=7.6Hz,1H),7.32(d,J=5.7Hz,2H),7.28–7.24(m,2H),7.21–7.02( m,2H),5.33(s,2H),3.75(t,J=4.7Hz,2H),3.42(t,J=5.0Hz,2H),2.34(s,6H),1.77-1.63(m,6H).
[0335] Example 60
[0336] This example provides a method for synthesizing compound Z60, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0337] (1) Synthesis of Compound Z60-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask. 30 mL of acetonitrile was added and stirred in an ice bath. 3-Methylbenzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0338] (2) Synthesis of Compound Z60-B: Dissolve 538 mg (1.55 mmol) of compound Z60-A in 10 mL of glacial acetic acid, heat with stirring, raise the temperature to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction, evaporate the glacial acetic acid under reduced pressure. The remaining solid is washed once with water and dissolved in ether with stirring until a white solid precipitates. The solid is collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0339] (3) Synthesis of Compound Z60-C: Place 200 mg (547.42 μmol) of Compound Z60-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0340] (4) Synthesis of Compound Z60: The synthesis method of compound Z60 refers to the synthesis method of Z1, except that Z1G is replaced by Z60-C and piperidine is replaced by 1,4-dioxa-8-azaspiro[4.5]decane. Product NMR data: 1H NMR (500MHz, CDCl3) δ7.59 (dd, J=7.9, 2.2Hz, 1H), 7.41 (d, J=2.2Hz, 1H), 7.28 (ddq, J=7.9, 2.1, 1.0 Hz,1H),7.20–7.14(m,2H),7.12(qd,J=1.7,1.1Hz,1H),7.08(ddt,J=7.5,1.4,0.8Hz,1H),5.04(t,J =1.0Hz,2H),3.91(s,3H),3.75(ddd,J=12.2,7.4,4.8Hz,2H),3.64(ddd,J=12.2,7.3,4.6Hz,2H),2. 32(d,J=0.7Hz,3H), 2.28(d,J=1.1Hz,3H), 1.90(dd,J=7.3,4.8Hz,2H), 1.85(dd,J=7.5,4.8Hz,2H).
[0341] Example 61
[0342] This example provides a method for synthesizing compound Z61, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0343] (1) Synthesis of compound Z61-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. 3-Hydroxybenzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA=10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0344] (2) Synthesis of Compound Z61-B: 538 mg (1.55 mmol) of Compound Z61-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0345] (3) Synthesis of Compound Z61-C: Place 200 mg (547.42 μmol) of Compound Z61-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0346] (4) Synthesis of Compound Z61: The synthesis method of compound Z61 refers to the synthesis method of Z1, except that Z1G is replaced by Z61-C. NMR data of the product: 1 H NMR (500MHz, CDCl3) δ7.59 (dd, J=7.9, 2.2Hz, 1H), 7.41 (d, J=2.1Hz, 1H), 7.20–7.14 (m,1H),7.18–7.11(m,1H),7.07(s,1H),6.96(ddq,J=7.9,2.1,1.0Hz,1H),6.80(tt, J=2.0,1.0Hz,1H),6.70(ddd,J=8.4,1.8,1.1Hz,1H),5.03(t,J=0.9Hz,2H),3.62–3. 54(m,2H),3.53–3.45(m,2H),2.28(d,J=1.1Hz,3H),2.23(s,2H),1.78–1.67(m,6H).
[0347] Example 62
[0348] This example provides a method for synthesizing compound Z62, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0349] (1) Synthesis of Compound Z62-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask. 30 mL of acetonitrile was added and stirred in an ice bath. 1-Bromomethyl-3-(2-methoxyethoxy)benzene was added. After the reaction was completed, the product was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA=10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0350] (2) Synthesis of Compound Z62-B: 538 mg (1.55 mmol) of Compound Z62-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0351] (3) Synthesis of Compound Z62-C: Place 200 mg (547.42 μmol) of Compound Z62-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0352] (4) Synthesis of Compound Z62: The synthesis method of compound Z62 refers to the synthesis method of Z1, except that Z1G is replaced by Z62-C. NMR data of the product: 1 H NMR (500MHz, CDCl3) δ7.59 (dd, J=7.9, 2.2Hz, 1H), 7.41 (d, J=2.1Hz, 1H), 7.21 (q, J=8.2Hz, 1H ),7.20–7.14(m,1H),7.01(ddq,J=8.0,2.1,0.9Hz,1H),6.91–6.85(m,2H),5.04(t,J=1.0Hz, 2H),4.05(t,J=4.7Hz,2H),3.75(dt,J=6.2,4.7Hz,2H),3.62–3.56(m,1H),3.57(tt,J=2.1,1 .1Hz,1H),3.53–3.45(m,2H),3.06(t,J=6.2Hz,1H),2.28(d,J=1.1Hz,3H),1.78–1.68(m,6H).
[0353] Example 63
[0354] This example provides a method for synthesizing compound Z63, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0355] (1) Synthesis of compound Z63-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. Benzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA=10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0356] (2) Synthesis of Compound Z63-B: 538 mg (1.55 mmol) of compound Z63-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0357] (3) Synthesis of Compound Z63-C: Place 200 mg (547.42 μmol) of Compound Z63-B in a two-necked flask under nitrogen. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0358] (4) Synthesis of Compound Z63: The synthesis method of compound Z63 refers to the synthesis method of Z1, except that Z1G is replaced by Z63-C and piperidine is replaced by azapine. Product NMR data: 1 HNMR (500MHz, CDCl3) δ7.59 (dd, J=7.9, 2.2Hz, 1H), 7.41 (d, J=2.1Hz, 1H), 7.34–7.23 (m, 5H), 7.17 (dq, J=8. 0,1.1Hz,1H),5.08(d,J=0.9Hz,2H),3.57(t,J=6.7Hz,2H),3.49–3.43(m,2H),2.28(d,J=1.1Hz,3H),1.72– 1.62(m,4H),1.60–1.49(m,4H).
[0359] Example 64
[0360] This example provides a method for synthesizing compound Z64, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0361] (1) Synthesis of Compound Z64-A: Compound Z1-D (500 mg, 2.06 mmol) and potassium carbonate (458.39 mg, 2.48 mmol) were placed in a 100 mL round-bottom flask. 30 mL of acetonitrile was added and stirred in an ice bath. 3-Bromomethylpyridine was added. After the reaction, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0362] (2) Synthesis of Compound Z64-B: 538 mg (1.55 mmol) of compound Z64-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0363] (3) Synthesis of Compound Z64-C: Place 200 mg (547.42 μmol) of Compound Z64-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0364] (4) Synthesis of compound Z64: The synthesis method of compound Z64 refers to the synthesis method of Z1, except that Z1G is replaced by Z64-C. Product NMR data: 1 H NMR(500MHz, CDCl3)δ8.60(dd,J=2.3,1.6Hz,1H),8.49–8.43(m,1H),7.73(dt ,J=7.9,2.2Hz,1H),7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.1Hz,1H),7.28(d d,J=8.0,4.2Hz,1H),7.17(dq,J=7.9,1.0Hz,1H),5.08(s,2H),3.62–3.54(m, 2H), 3.53–3.45 (m, 2H), 2.28 (d, J = 1.1Hz, 3H), 2.23 (s, 2H), 1.78–1.68 (m, 6H).
[0365] Example 65
[0366] This example provides a method for synthesizing compound Z65, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0367] (1) Synthesis of Compound Z65-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask. 30 mL of acetonitrile was added and stirred in an ice bath. 3-Ethylbenzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA=10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0368] (2) Synthesis of Compound Z65-B: 538 mg (1.55 mmol) of compound Z65-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0369] (3) Synthesis of Compound Z65-C: Place 200 mg (547.42 μmol) of Compound Z65-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0370] (4) Synthesis of Compound Z65: The synthesis method of compound Z65 refers to the synthesis method of Z1, except that Z1G is replaced by Z65-C and piperidine is replaced by octahydro-2H-pyrido[3,4-d][1,3]oxazin-2-one. Product NMR data: 1HNMR(500MHz, CDCl3) δ7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.1Hz,1H),7.33(ddq,J=8.2,2.1,1.0Hz,1 H),7.23–7.07(m,3H),5.85(d,J=7.1Hz,1H),5.12–5.01(m,2H),4.20(ddt,J=7.3,5.7,2.9Hz,1H),4.19–4 .08(m,2H),3.90(dd,J=12.5,2.9Hz,1H),3.78(dd,J=12.5,2.9Hz,1H),3.70–3.58(m,2H),2.68–2.60(m,2 H),2.30–2.21(m,7H),1.79(dddd,J=11.8,8.4,6.6,5.1Hz,1H),1.73–1.62(m,1H),1.23(t,J=7.2Hz,3H).
[0371] Example 66
[0372] This example provides a method for synthesizing compound Z66, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0373] (1) Synthesis of compound Z66-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. Benzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA=10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0374] (2) Synthesis of Compound Z66-B: 538 mg (1.55 mmol) of compound Z66-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0375] (3) Synthesis of Compound Z66-C: Place 200 mg (547.42 μmol) of Compound Z66-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0376] (4) Synthesis of Compound Z66: The synthesis method of compound Z66 refers to the synthesis method of Z1, except that Z1G is replaced by Z66-C and piperidine is replaced by 1-methyl-1,4-diazepane. Product NMR data: 1 H NMR(500MHz, CDCl3)δ7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.1Hz,1H),7.34–7.23( m,5H),7.17(dq,J=8.0,1.1Hz,1H),5.09(t,J=0.9Hz,2H),3.61(dd,J=7.0,6.2Hz,1H ),3.57–3.49(m,2H),3.46(dd,J=7.1,6.4Hz,1H),2.69(dd,J=7.0,6.2Hz,1H),2.66– 2.60(m,1H),2.56(ddd,J=8.4,7.2,6.5Hz,2H),2.32–2.26(m,5H),1.87–1.74(m,2H).
[0377] Example 67
[0378] This example provides a method for synthesizing compound Z67, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0379] (1) Synthesis of Compound Z67-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask. 30 mL of acetonitrile was added and stirred in an ice bath. 3-Ethylbenzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA=10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0380] (2) Synthesis of Compound Z67-B: Dissolve 538 mg (1.55 mmol) of compound Z67-A in 10 mL of glacial acetic acid, heat with stirring, raise the temperature to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction, evaporate the glacial acetic acid under reduced pressure. The remaining solid is washed once with water and dissolved in ether with stirring until a white solid precipitates. The solid is collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0381] (3) Synthesis of Compound Z67-C: Place 200 mg (547.42 μmol) of Compound Z67-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0382] (4) Synthesis of Compound Z67: The synthesis method of compound Z67 refers to the synthesis method of Z1, except that Z1G is replaced by Z67-C and piperidine is replaced by hexahydrooxazolo[4,5-c]pyridin-2(3H)-one. NMR data of the product: 1 H NMR (500MHz, CDCl3) δ7.59 (dd, J=7.9, 2.2Hz, 1H), 7.41 (d, J=2.1Hz, 1H), 7.33 (ddq, J=8.2, 2.1, 1.0Hz,1H),7.23–7.07(m,3H),7.04(s,1H),5.12–5.01(m,2H),4.18(d,J=1.8Hz,2H),3.85(d,J =12.3Hz,1H),3.75(d,J=12.4Hz,1H),3.58–3.50(m,2H),2.68–2.60(m,2H),2.28(d,J=1.1Hz,3 H), 2.23 (s, 2H), 1.92–1.83 (m, 1H), 1.83–1.75 (m, 1H), 1.79–1.68 (m, 2H), 1.23 (t, J = 7.2Hz, 3H).
[0383] Example 68
[0384] This example provides a method for synthesizing compound Z68, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0385] (1) Synthesis of Compound Z68-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask. 30 mL of acetonitrile was added and stirred in an ice bath. 3-Methylbenzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0386] (2) Synthesis of Compound Z68-B: 538 mg (1.55 mmol) of Compound Z68-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0387] (3) Synthesis of Compound Z68-C: Place 200 mg (547.42 μmol) of Compound Z68-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0388] (4) Synthesis of Compound Z68: The synthesis method of compound Z68 refers to the synthesis method of Z1, except that Z1G is replaced by Z68-C and piperidine is replaced by 4-(1H-pyrazol-4-yl)piperidine. Product NMR data: 1 H NMR(500MHz, CDCl3)δ7.59(dd,J=7.9,2.2Hz,1H),7.43–7.36(m,2H),7.34(d, J=1.6Hz,1H),7.28(ddq,J=7.9,2.1,1.0Hz,1H),7.20–7.05(m,4H),5.04(t,J =1.0Hz,2H),3.60–3.51(m,4H),3.17(p,J=5.9Hz,1H),2.32(d,J=0.7Hz,3H), 2.28(d,J=1.1Hz,3H), 2.14(dtd,J=12.7,7.3,5.9Hz,2H), 1.91–1.81(m,2H).
[0389] Example 69
[0390] This example provides a method for synthesizing compound Z69, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0391] (1) Synthesis of compound Z69-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. Benzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA=10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0392] (2) Synthesis of Compound Z69-B: 538 mg (1.55 mmol) of Compound Z69-A was dissolved in 10 mL of glacial acetic acid, heated with stirring, and then the temperature was raised to 70°C. 5 mL of concentrated hydrochloric acid was added, and the mixture was refluxed at 110°C. After the reaction, the glacial acetic acid was evaporated under reduced pressure. The remaining solid was washed once with water and dissolved in ether with stirring until a white solid precipitated. The solid was collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0393] (3) Synthesis of Compound Z69-C: Place 200 mg (547.42 μmol) of Compound Z69-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0394] (4) Synthesis of Compound Z69: The synthesis method of compound Z69 refers to the synthesis method of Z1, except that Z1G is replaced by Z69-C and piperidine is replaced by 1,4-diazepane-1-carboxylic acid tert-butyl ester. The resulting product is then de-Bocated using 3M HCl in ethyl acetate to obtain product Z69. Product NMR data: 1H NMR (500MHz, CDCl3) δ7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.1Hz,1H),7.34–7.23(m,5H),7.17(dq,J=8.0,1.1Hz,1H),5.08(d,J=0.9Hz, 2H),3.62(t,J=6.0Hz,1H),3.56–3.42(m,3H),2.83–2.71(m,4H),2.28(d,J=1.1Hz,3H),2.23(s,2H),2.21–2.13(m,1H),1.89–1.81(m,1H).
[0395] Example 70
[0396] This example provides a method for synthesizing compound Z70, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0397] (1) Synthesis of Compound Z70-A: Compound Z1-D (500 mg, 2.06 mmol) and potassium carbonate (458.39 mg, 2.48 mmol) were placed in a 100 mL round-bottom flask. 30 mL of acetonitrile was added and stirred in an ice bath. 4-Fluorobenzyl bromide was added. After the reaction, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA = 10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0398] (2) Synthesis of Compound Z70-B: Dissolve 538 mg (1.55 mmol) of compound Z70-A in 10 mL of glacial acetic acid, heat with stirring, raise the temperature to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction, evaporate the glacial acetic acid under reduced pressure. The remaining solid is washed once with water and dissolved in ether with stirring until a white solid precipitates. The solid is collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0399] (3) Synthesis of Compound Z70-C: Place 200 mg (547.42 μmol) of Compound Z70-B in a two-necked flask under nitrogen atmosphere. Pour 2 mL of redistilled DCM into the flask and add a drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0400] (4) Synthesis of Compound Z70: The synthesis method of compound Z70 refers to the synthesis method of Z1, except that Z1G is replaced by Z70-C. NMR data of the product: 1 H NMR (500MHz, CDCl3) δ7.59 (dd, J=7.9, 2.2Hz, 1H), 7.41 (d, J=2.1Hz, 1H), 7.28 (ddt, J= 8.2,5.0,1.1Hz,2H),7.17(dq,J=8.0,1.1Hz,1H),7.13–7.05(m,2H),5.06(t,J=1.0Hz, 2H),3.62–3.56(m,1H),3.57(dt,J=4.5,1.8Hz,1H),3.53–3.45(m,2H),2.28(d,J=1.1Hz,3H),1.78–1.68(m,6H).
[0401] Example 71
[0402] This example provides a method for synthesizing compound Z71, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0403] (1) Synthesis of compound Z71-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath. Benzyl bromide was added. After the reaction was completed, the mixture was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The concentrate was purified by column chromatography (PE:EA=10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0404] (2) Synthesis of Compound Z71-B: Dissolve 538 mg (1.55 mmol) of compound Z71-A in 10 mL of glacial acetic acid, heat with stirring, raise the temperature to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction, evaporate the glacial acetic acid under reduced pressure. The remaining solid is washed once with water and dissolved in ether with stirring until a white solid precipitates. The solid is collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0405] (3) Synthesis of Compound Z71-C: Place 200 mg (547.42 μmol) of Compound Z71-B in a two-necked flask under nitrogen. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0406] (4) Synthesis of Compound Z71: The synthesis method of compound Z71 refers to the synthesis method of Z1, except that Z1G is replaced by Z71-C, piperidine is replaced by tert-butyl piperazine-1-carboxylate, and the resulting product is de-Bocated using 3M HCl in ethyl acetate to obtain product Z71. Product NMR data: 1 H NMR (500MHz, CDCl3) δ7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.1Hz,1H),7.34–7.23(m,5H),7.17(dq,J=8.0,1.1Hz,1H),5.09(t,J=0.9Hz,2H ), 3.65 (dd, J = 5.7, 2.9 Hz, 2H), 3.58 ( dd, J = 5.8, 3.0 Hz, 2H), 2.86 ( ddt, J = 22.7, 5.7, 3.1 Hz, 4H), 2.28 ( d, J = 1.1 Hz, 3H), 1.91 ( p, J = 3.5 Hz, 1H).
[0407] Example 72
[0408] This example provides a method for synthesizing compound Z72, as shown below. The reaction conditions are: (1) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate; (2) HCl, glacial acetic acid, 110°C; (3) oxalyl chloride, DCM, DMF, N2, rt; and (4) piperidine, Et3N, DCM, 0°C.
[0409] (1) Synthesis of compound Z72-A: Compound Z1-D (Z1D, 500 mg 2.06 mmol) and 458.39 mg (2.48 mmol) of potassium carbonate were placed in a 100 mL round-bottom flask, 30 mL of acetonitrile was added and stirred in an ice bath, and 4-bromomethyl-1-((trimethylsilyl)methyl)-1H-1,2,3-triazole was added. After the reaction was completed, the product was extracted, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by column chromatography (PE:EA=10:1) to obtain 538 mg of a white solid with a yield of 75.25%.
[0410] (2) Synthesis of Compound Z72-B: Dissolve 538 mg (1.55 mmol) of compound Z72-A in 10 mL of glacial acetic acid, heat with stirring, raise the temperature to 70°C, add 5 mL of concentrated hydrochloric acid, and reflux at 110°C. After the reaction, evaporate the glacial acetic acid under reduced pressure. The remaining solid is washed once with water and dissolved in ether with stirring until a white solid precipitates. The solid is collected by filtration to obtain 400 mg of a white solid with a yield of 70.48%.
[0411] (3) Synthesis of Compound Z72-C: Place 200 mg (547.42 μmol) of Compound Z72-B in a two-necked flask under nitrogen. Pour 2 mL of redistilled DCM into the flask and add one drop of anhydrous DMF. Stir at room temperature. Dilute oxalyl chloride with 2 mL of redistilled DCM and pour into the flask. After the reaction is complete, evaporate under reduced pressure.
[0412] (4) Synthesis of Compound Z72: The synthesis method of compound Z72 refers to the synthesis method of Z1, except that Z1G is replaced by Z72-C. Product NMR data: 1 H NMR(500MHz, CDCl3)δ7.63–7.56(m,2H),7.50-7.32(m,1H),7.17(dq,J=7.9,1.0Hz,1H),5.02(s,2H),3.6 2–3.54(m,2H),3.53–3.45(m,2H),3.16(s,2H),2.28(s,3H),2.23(s,3H),1.78–1.68(m,6H),0.05(s,9H).
[0413] Example 73
[0414] This example provides a method for synthesizing compound Z73, as shown below. The reaction conditions are as follows: (1) NaNO2, HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K2CO3, acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N2; and (6) piperidine, Et3N, DCM, 0°C.
[0415] (1) Synthesis of compound Z73-B: The synthesis of compound Z73-B was based on compound Z1C, except that compound Z1A was replaced by 2,3-dihydrobenzofuran-5-amine.
[0416] (2) Synthesis of compound Z73-C: The synthesis of compound Z73-C was based on compound Z1D, except that compound Z1C was replaced by compound Z73-B.
[0417] (3) Synthesis of compound Z73-D: The synthesis of compound Z73-D was carried out with reference to compound Z1E, except that compound Z1D was replaced by compound Z73-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.
[0418] (4) Synthesis of compound Z73-E: The synthesis of compound Z73-E was based on compound Z1F, except that compound Z1E was replaced by compound Z73-D.
[0419] (5) Synthesis of compound Z73-F: The synthesis of compound Z73-F was based on compound Z1G, except that compound Z1F was replaced by compound Z73-E.
[0420] (6) Synthesis of Compound Z73: The synthesis method of compound Z73 refers to the synthesis method of Z1, except that Z1G is replaced by Z73-C. NMR data of the product: 1 H NMR (500MHz, CDCl3) δ7.42–7.36(m,2H),7.20(dd,J=8.1,7.4Hz,1H),7.01(ddq,J=8.1,2.2,1.1Hz,1H),6.89( tt,J=2.3,1.0Hz,1H),6.87–6.83(m,1H),6.81(ddd,J=7.3,2.2,1.1Hz,1H),5.02(t,J=1.0Hz,2H),4.50(ddd,J =11.4,5.1,3.1Hz,2H),3.81(s,2H),3.75(d,J=12.6Hz,1H),3.68(d,J=12.6Hz,1H),3.18(ddd,J=5.1,3.2,0. 9Hz, 1H), 3.11 (ddd, J=5.2, 3.2, 0.9Hz, 1H), 2.65 (dt, J=6.2, 3.4Hz, 4H), 1.61–1.53 (m, 4H), 1.49–1.41 (m, 2H).
[0421] Example 74
[0422] This example provides a method for synthesizing compound Z74, as shown below. The reaction conditions are as follows: (1) NaNO2, HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K2CO3, acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N2; and (6) piperidine, Et3N, DCM, 0°C.
[0423] (1) Synthesis of compound Z74-B: The synthesis of compound Z74-B was based on compound Z1C, except that compound Z1A was replaced by 2,3-dihydrobenzo[b][1,4]dioxin-6-amine.
[0424] (2) Synthesis of compound Z74-C: The synthesis of compound Z74-C was based on compound Z1D, except that compound Z1C was replaced by compound Z74-B.
[0425] (3) Synthesis of compound Z74-D: The synthesis of compound Z74-D was carried out with reference to compound Z1E, except that compound Z1D was replaced by compound Z74-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.
[0426] (4) Synthesis of compound Z74-E: The synthesis of compound Z74-E was based on compound Z1F, except that compound Z1E was replaced by compound Z74-D.
[0427] (5) Synthesis of compound Z74-F: The synthesis of compound Z74-F was based on compound Z1G, except that compound Z1F was replaced by compound Z74-E.
[0428] (6) Synthesis of Compound Z74: The synthesis of Compound Z74 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z74-F. 1 H NMR (500MHz, CDCl3) δ7.28 (dd, J=8.2, 2.2Hz, 1H), 7.20 (dd, J=8.1, 7.4Hz, 1H), 7.04–6.98(m,2H),6.89(dp,J=1.9,0.9Hz,1H),6.85(d,J=8.2Hz,1H),6.81(ddd ,J=7.3,1.8,1.1Hz,1H),5.04(t,J=1.0Hz,2H),4.27(s,4H),3.81(s,2H),3.62– 3.56(m,1H),3.57(dt,J=4.5,1.8Hz,1H),3.53–3.45(m,2H),1.78–1.68(m,6H).
[0429] Example 75
[0430] This example provides a method for synthesizing compound Z75, as shown below. The reaction conditions are as follows: (1) NaNO2, HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K2CO3, acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N2; and (6) piperidine, Et3N, DCM, 0°C.
[0431] (1) Synthesis of compound Z75-B: The synthesis of compound Z75-B was based on compound Z1C, except that compound Z1A was replaced by 2-methyl-2H-indazol-5-amine.
[0432] (2) Synthesis of compound Z75-C: The synthesis of compound Z75-C was based on compound Z1D, except that compound Z1C was replaced by compound Z75-B.
[0433] (3) Synthesis of compound Z75-D: The synthesis of compound Z75-D was based on compound Z1E, except that compound Z1D was replaced by compound Z75-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.
[0434] (4) Synthesis of compound Z75-E: The synthesis of compound Z75-E was based on compound Z1F, except that compound Z1E was replaced by compound Z75-D.
[0435] (5) Synthesis of compound Z75-F: The synthesis of compound Z75-F was based on compound Z1G, except that compound Z1F was replaced by compound Z75-E.
[0436] (6) Synthesis of Compound Z75: The synthesis of Compound Z75 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z75-F. 1H NMR (500MHz, CDCl3) δ8.10(t,J=2.0Hz,1H),7.94(d,J=1.8Hz,1H),7.75(dd,J=6.7,2.3Hz,1H) ,7.62(d,J=6.8Hz,1H),7.20(dd,J=8.1,7.4Hz,1H),7.01(ddq,J=8.1,2.1,1.0Hz,1H),6.89(tt ,J=1.9,1.0Hz,1H),6.81(ddd,J=7.3,1.8,1.1Hz,1H),5.04(t,J=1.0Hz,2H),3.93(s,3H),3.8 1(s,2H),3.62–3.56(m,1H),3.57(tt,J=2.1,1.1Hz,1H),3.53–3.45(m,2H),1.78–1.68(m,6H).
[0437] Example 76
[0438] This example provides a method for synthesizing compound Z76, as shown below. The reaction conditions are as follows: (1) NaNO2, HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K2CO3, acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N2; and (6) piperidine, Et3N, DCM, 0°C.
[0439] (1) Synthesis of compound Z76-B: The synthesis of compound Z76-B was carried out with reference to compound Z1C, except that compound Z1A was replaced by compound 2,3-dihydro-1H-inden-5-amine.
[0440] (2) Synthesis of compound Z76-C: The synthesis of compound Z76-C was based on compound Z1D, except that compound Z1C was replaced by compound Z76-B.
[0441] (3) Synthesis of compound Z76-D: The synthesis of compound Z76-D was based on compound Z1E, except that compound Z1D was replaced by compound Z77-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.
[0442] (4) Synthesis of compound Z76-E: The synthesis of compound Z76-E was based on compound Z1F, except that compound Z1E was replaced by compound Z76-D.
[0443] (5) Synthesis of compound Z76-F: The synthesis of compound Z76-F was based on compound Z1G, except that compound Z1F was replaced by compound Z76-E.
[0444] (6) Synthesis of Compound Z76: The synthesis of Compound Z76 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z76-F. 1 H NMR (500MHz, CDCl3) δ7.41 (dd, J=1.9, 1.0Hz, 1H), 7.32 (dd, J=8.0, 1.9Hz, 1H), 7.24–7.1 7(m,2H),7.01(ddq,J=8.1,2.1,0.9Hz,1H),6.89(tt,J=2.0,0.9Hz,1H),6.81(ddd,J=7.3 ,1.8,1.1Hz,1H),5.04(t,J=1.0Hz,2H),3.81(s,2H),3.62–3.56(m,1H),3.57(dt,J=4.5 ,1.8Hz,1H),3.53–3.45(m,2H),2.91–2.81(m,4H),2.16–2.04(m,2H),1.78–1.67(m,6H).
[0445] Example 77
[0446] This example provides a method for synthesizing compound Z77, as shown below. The reaction conditions are as follows: (1) NaNO2, HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K2CO3, acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N2; and (6) piperidine, Et3N, DCM, 0°C.
[0447] (1) Synthesis of compound Z77-B: The synthesis of compound Z77-B was based on compound Z1C, except that compound Z1A was replaced by compound 5,6,7,8-tetrahydronaphthalene-2-amine.
[0448] (2) Synthesis of compound Z77-C: The synthesis of compound Z77-C was based on compound Z1D, except that compound Z1C was replaced by compound Z77-B.
[0449] (3) Synthesis of compound Z77-D: The synthesis of compound Z77-D was based on compound Z1E, except that compound Z1D was replaced by compound Z77-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.
[0450] (4) Synthesis of compound Z77-E: The synthesis of compound Z77-E was based on compound Z1F, except that compound Z1E was replaced by compound Z77-D.
[0451] (5) Synthesis of compound Z77-F: The synthesis of compound Z77-F was based on compound Z1G, except that compound Z1F was replaced by compound Z77-E.
[0452] (6) Synthesis of Compound Z77: The synthesis of Compound Z77 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z77-F. 1 H NMR (500MHz, CDCl3) δ7.34–7.29(m,2H),7.20(dd,J=8.1,7.4Hz,1H),7.13(dt,J=8.5,1. 1Hz, 1H), 7.01 (ddq, J=8.1, 2.1, 0.9Hz, 1H), 6.89 (tt, J=1.9, 0.9Hz, 1H), 6.81 (ddd, J=7.3 ,1.8,1.1Hz,1H),5.04(t,J=1.0Hz,2H),3.81(s,2H),3.62–3.56(m,1H),3.57(tt,J=2.1 ,1.1Hz,1H),3.53–3.45(m,2H),2.82–2.70(m,4H),1.79–1.72(m,3H),1.75–1.67(m,7H).
[0453] Example 78
[0454] This example provides a method for synthesizing compound Z78, as shown below. The reaction conditions are as follows: (1) NaNO2, HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K2CO3, acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N2; and (6) piperidine, Et3N, DCM, 0°C.
[0455] (1) Synthesis of compound Z78-B: The synthesis of compound Z78-B was based on compound Z1C, except that compound Z1A was replaced by 2-propyl-1,2,3,4-tetrahydroisoquinolin-7-amine.
[0456] (2) Synthesis of compound Z78-C: The synthesis of compound Z78-C was based on compound Z1D, except that compound Z1C was replaced by compound Z78-B.
[0457] (3) Synthesis of compound Z78-D: The synthesis of compound Z78-D was based on compound Z1E, except that compound Z1D was replaced by compound Z78-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.
[0458] (4) Synthesis of compound Z78-E: The synthesis of compound Z78-E was based on compound Z1F, except that compound Z1E was replaced by compound Z78-D.
[0459] (5) Synthesis of compound Z78-F: The synthesis of compound Z78-F was based on compound Z1G, except that compound Z1F was replaced by compound Z78-E.
[0460] (6) Synthesis of Compound Z78: The synthesis of Compound Z78 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z78-F. 1 H NMR(500MHz, CDCl3)δ7.58(dd,J=7.9,2.2Hz,1H),7.47(dt,J=2.2,1.1Hz,1H),7.25–7.17(m,2H),7.01(ddq,J =8.1,2.1,0.9Hz,1H),6.89(tt,J=1.9,0.9Hz,1H),6.81(ddd,J=7.3,1.8,1.1Hz,1H),5.04(t,J=1.0Hz,2H),3. 81(s,2H),3.71(dd,J=12.4,1.1Hz,1H),3.63(dd,J=12.5,1.1Hz,1H),3.62–3.54(m,2H),3.53–3.45(m,2H),2 .94–2.75(m,5H),2.53(t,J=6.2Hz,2H),1.78–1.68(m,6H),1.51(qt,J=7.9,6.2Hz,2H),0.89(t,J=7.9Hz,3H).
[0461] Example 79
[0462] This example provides a method for synthesizing compound Z79, as shown below. The reaction conditions are as follows: (1) NaNO2, HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K2CO3, acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N2; and (6) piperidine, Et3N, DCM, 0°C.
[0463] (1) Synthesis of compound Z79-B: The synthesis of compound Z79-B was based on compound Z1C, except that compound Z1A was replaced by compound 6,7-dihydro-5H-cyclopenta[b]pyridin-3-amine.
[0464] (2) Synthesis of compound Z79-C: The synthesis of compound Z79-C was based on compound Z1D, except that compound Z1C was replaced by compound Z79-B.
[0465] (3) Synthesis of compound Z79-D: The synthesis of compound Z79-D was based on compound Z1E, except that compound Z1D was replaced by compound Z79-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.
[0466] (4) Synthesis of compound Z79-E: The synthesis of compound Z79-E was based on compound Z1F, except that compound Z1E was replaced by compound Z79-D.
[0467] (5) Synthesis of compound Z79-F: The synthesis of compound Z79-F was based on compound Z1G, except that compound Z1F was replaced by compound Z79-E.
[0468] (6) Synthesis of Compound Z79: The synthesis of Compound Z79 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z79-F. 1 H NMR (500MHz, CDCl3) δ8.47(d,J=2.0Hz,1H),8.18(d,J=2.0Hz,1H),7.20(dd,J=8.1,7.4Hz,1H),7 .01(ddq,J=8.1,2.1,1.0Hz,1H),6.89(tt,J=1.9,0.9Hz,1H),6.81(ddd,J=7.3,1.8,1.1Hz,1H), 5.04(t,J=1.0Hz,2H),3.81(s,2H),3.62–3.56(m,1H),3.57(dq,J=3.3,2.1,1.7Hz,1H),3.53–3. 45(m,2H),2.98(dd,J=7.0,5.2Hz,1H),2.95–2.85(m,3H),2.32–2.20(m,2H),1.78–1.68(m,6H).
[0469] Example 80
[0470] This example provides a method for synthesizing compound Z80, as shown below. The reaction conditions are as follows: (1) NaNO2, HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K2CO3, acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N2; and (6) piperidine, Et3N, DCM, 0°C.
[0471] (1) Synthesis of compound Z80-B: The synthesis of compound Z80-B was based on compound Z1C, except that compound Z1A was replaced by compound 5,6-dimethylpyridin-3-amine.
[0472] (2) Synthesis of compound Z80-C: The synthesis of compound Z80-C was based on compound Z1D, except that compound Z1C was replaced by compound Z80-B.
[0473] (3) Synthesis of compound Z80-D: The synthesis of compound Z80-D was based on compound Z1E, except that compound Z1D was replaced by compound Z80-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.
[0474] (4) Synthesis of compound Z80-E: The synthesis of compound Z80-E was based on compound Z1F, except that compound Z1E was replaced by compound Z80-D.
[0475] (5) Synthesis of compound Z80-F: The synthesis of compound Z80-F was based on compound Z1G, except that compound Z1F was replaced by compound Z80-E.
[0476] (6) Synthesis of Compound Z80: The synthesis of Compound Z80 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z80-F. 1 H NMR (500MHz, CDCl3) δ8.38(d,J=1.8Hz,1H),7.77(d,J=2.0Hz,1H),7.20(dd,J =8.1,7.4Hz,1H),7.01(ddq,J=8.1,2.2,1.0Hz,1H),6.89(tt,J=2.0,0.9Hz,1H ),6.81(ddd,J=7.3,1.8,1.1Hz,1H),5.04(t,J=1.0Hz,2H),3.81(s,2H),3.62 –3.54(m,2H),3.53–3.45(m,2H),2.38(s,2H),2.29(s,2H),1.78–1.68(m,5H).
[0477] Example 81
[0478] This example provides a method for synthesizing compound Z81, as shown below. The reaction conditions are as follows: (1) NaNO2, HCl, AcONa, pyridine, 0°C; (2) AcONa, AcOH, 110°C; (3) K2CO3, acetonitrile; (4) HCl, AcOH, 110°C; (5) oxalyl chloride, DMF, DCM, N2; and (6) piperidine, Et3N, DCM, 0°C.
[0479] (1) Synthesis of compound Z81-B: The synthesis of compound Z81-B was based on compound Z1C, except that compound Z1A was replaced by 2-methylisoindolin-5-amine.
[0480] (2) Synthesis of compound Z81-C: The synthesis of compound Z81-C was carried out with reference to compound Z1D, except that compound Z1C was replaced by compound Z81-B.
[0481] (3) Synthesis of compound Z81-D: The synthesis of compound Z81-D was based on compound Z1E, except that compound Z1D was replaced by compound Z81-C, and benzyl bromide was replaced by 3-methoxybenzyl bromide.
[0482] (4) Synthesis of compound Z81-E: The synthesis of compound Z81-E was based on compound Z1F, except that compound Z1E was replaced by compound Z81-D.
[0483] (5) Synthesis of compound Z81-F: The synthesis of compound Z81-F was based on compound Z1G, except that compound Z1F was replaced by compound Z81-E.
[0484] (6) Synthesis of Compound Z81: The synthesis of Compound Z81 was based on the same method as Compound Z1, except that Compound Z1G was replaced by Compound Z81-F. 1 H NMR (500MHz, CDCl3) δ7.57 (dd, J=8.2, 2.2Hz, 1H), 7.52 (dt, J=2.1, 1.0Hz, 1H), 7.24–7 .16(m,2H),7.01(ddq,J=8.1,2.1,1.0Hz,1H),6.89(tt,J=1.9,1.0Hz,1H),6.81(ddd,J =7.3,1.8,1.1Hz,1H),5.04(t,J=1.0Hz,2H),3.93–3.87(m,4H),3.81(s ,2H),3.62–3.56(m,1H),3.57(tt,J=2.1,1.1Hz,1H),3.53–3.45(m,2H).
[0485] Example 82
[0486] This example provides a method for synthesizing compound Z82, as shown below.
[0487] Synthesis of Compound Z82-A: 3,4-Dimethylboronic acid (500 mg, 4.46 mmol), uracil (1340 mg, 8.92 mmol), copper acetate (1640 mg, 4.46 mmol), and N,N,N',N'-tetramethylethylenediamine (1040 mg, 8.92 mmol) were dissolved in a mixture of 400 mL of MeOH and 100 mL of water and allowed to stand at room temperature overnight. The solvent was mostly removed by rotary evaporation. After partial removal of the solvent, the product was extracted with ethyl acetate and the organic phase was purified by spin column chromatography to yield Z82-A as a white solid. 1 H NMR (500MHz, CDCl3) δ9.89 (s, 1H), 8.22 (d, J = 7.3Hz, 1H), 7.31 (d, J = 1.7Hz, 1H), 7.17–6.97 (m, 2H), 5.87 (d, J = 7.3Hz, 1H), 2.28 (s, 1H), 2.22 (s, 3H).
[0488] Synthesis of compound Z82-B: The synthesis of compound Z82-B was carried out by referring to the synthesis of compound Z15-A, except that compound Z1-D was replaced by Z82-A.
[0489] Synthesis of compound Z82-C: Z82-B (650 mg) was placed in a double-necked flask and dissolved in 1 ml of anhydrous DMF under nitrogen. In an EP tube, 0.7 ml of dry DMF was added, and 0.5 ml of POCl3 was slowly added. This was then slowly added dropwise to the DMF solution of Z82-B in an ice bath. The reaction was heated to 90°C and allowed to react for two hours. The reaction was then quenched with a 2N aqueous solution of NaOH. Extraction was performed with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate. The organic solvent was removed by distillation under reduced pressure and purified by column chromatography to obtain Z82-C as a white solid.
[0490] Synthesis of compound Z82-D: Dissolve Z82-C (110 mg) in a mixture of 6 mL of tert-butanol and 6 mL of tetrahydrofuran, and add 1 mL of 2-methyl-2-butene dropwise. Dissolve sodium dihydrogen phosphate (264 mg) and sodium chlorite (76 mg) in water and slowly add the Z82-D solution. Allow the reaction to complete at room temperature for 1 h, then remove the solvent by rotary evaporation. Adjust the pH to acidic with 1N HCl, extract with ethyl acetate, and dry over anhydrous sodium sulfate. Rotary evaporation removes the solvent to yield Z82-D as a white solid.
[0491] Synthesis of Compound Z82: Compound Z82-D (114 mg) was dissolved in 2 ml of anhydrous dichloromethane. 1-Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (74 mg), 1-hydroxybenzotriazole (53 mg), and piperidine (33 mg) were added sequentially in an ice bath. The reaction was allowed to proceed at room temperature for 5 hours. The mixture was extracted with water, and the organic phase was dried over anhydrous sodium sulfate. The organic solvent was removed by rotary evaporation and purified by column chromatography to yield Z82 as a white solid. 1 H NMR(500MHz, CDCl3)δ8.50(s,1H),7.27–7.17(m,2H),7.14–7.09(m,1H),7.06(dd,J=8.1,2.2Hz ,1H),7.01(ddq,J=8.1,2.1,1.0Hz,1H),6.89(tt,J=1.9,0.9Hz,1H),6.81(ddd,J=7.3,1.8,1.1 Hz,1H),5.04(t,J=1.0Hz,2H),3.81(s,3H),3.59–3.53(m,1H),3.53(dd,J=4.4,1.8Hz,1H),3.5 1–3.47(m,1H),3.47(ddd,J=8.8,3.4,2.0Hz,1H),2.28(s,3H),2.22(s,3H),1.79–1.68(m,6H).
[0492] Example 83
[0493] This example provides a method for synthesizing compound Z83. Compound Z83 was synthesized by placing compound Z82-C and sodium acetate borohydride in a two-necked flask. Under nitrogen, 7 ml of anhydrous dichloromethane was added. Piperidine was then added dropwise to the flask. The reaction was allowed to proceed overnight at room temperature. After adding saturated sodium bicarbonate solution and stirring for half an hour, the mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, and the organic solvent was removed by rotary evaporation. Purification by column chromatography yielded Z83 as a white solid. 1H NMR (500MHz, CDCl3) δ8.25 (s, 1H), 7.26–7.24 (m, 2H), 7.20 (dd, J = 8.1, 7.4Hz, 2H), 7.11 (dq, J = 8.1, 1. 0Hz,2H),7.07(dd,J=8.1,2.2Hz,2H),7.01(ddq,J=8.1,2.2,1.1Hz,2H),6.89(tt,J=1.9,0.9Hz,2H),6 .81(ddd,J=7.3,1.8,1.1Hz,2H),5.01(s,2H),3.81(s,4H),3.71(d,J=1.0Hz,3H),2.57(dd,J=6.2,3. 5Hz,2H),2.53(dd,J=6.2,3.5Hz,2H),2.28(s,3H),2.22(s,3H),1.60–1.52(m,4H),1.48–1.42(m,2H).
[0494] Example 84
[0495] The synthesis of compound Z84 refers to the synthesis of Z17, except that 3-methylbenzyl bromide in the synthesis of Z17 is replaced by 3-methoxyphenethyl bromide. 1 H NMR (500MHz, CDCl3) δ7.59 (dd, J=7.9, 2.2Hz, 1H), 7.41 (d, J=2.1Hz, 1H), 7.21–7.14 (m,2H),6.92(ddq,J=7.7,2.2,1.1Hz,1H),6.78(ddd,J=7.5,2.2,1.1Hz,1H),6.73(t t,J=2.2,1.0Hz,1H),4.11(t,J=6.5Hz,2H),3.80(s,3H),3.62–3.56(m,2H),3.53–3. 45(m,2H),2.92(tt,J=6.5,1.1Hz,2H),2.28(s,3H),2.23(s,2H),1.78–1.68(m,6H).
[0496] Example 85
[0497] The synthesis of compound Z85 refers to the synthesis of Z17, except that 3-methylbenzyl bromide in the synthesis of Z17 is replaced by 3-methoxyphenylpropyl bromide. 1H NMR(500MHz, CDCl3)δ7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.1Hz,1H),7.21–7.14(m,2H),6.86(ddq,J=7.7, 2.1,1.0Hz,1H),6.78(ddd,J=7.5,2.0,1.2Hz,1H),6.71(tt,J=2.0,1.0Hz,1H),3.95(dt,J=12.6,6.9Hz,1H),3 .84(dt,J=12.7,6.8Hz,1H),3.80(s,2H),3.62–3.56(m,1H),3.57(tt,J=2.1,1.1Hz,1H),3.53–3.45(m,2H),2 .69(tt,J=8.5,1.0Hz,2H),2.28(d,J=1.1Hz,3H),2.23(s,2H),1.93(tt,J=8.4,6.9Hz,2H),1.78–1.68(m,6H).
[0498] Example 86
[0499] This example provides a method for synthesizing compound Z86, as shown below.
[0500] Synthesis of compound Z86-A: Compound Z15-A (489 mg) and Pd / C (1440 mg, 5%) were placed in a double-necked flask. 20 ml of methanol and 2 ml of concentrated hydrochloric acid were added under hydrogen atmosphere. The reaction was allowed to proceed overnight at room temperature. The mixture was filtered through diatomaceous earth and the organic solvent was removed by rotary evaporation to obtain a white solid. The solid was dissolved in water and the pH was adjusted to alkaline using a saturated aqueous solution of NaHCO3. The solid was extracted with dichloromethane and dried over anhydrous sodium sulfate. The organic solvent was removed by rotary evaporation and purified by column chromatography to obtain a colorless, transparent oil Z86-A. The resulting NMR 1H NMR (500MHz, CDCl3) δ7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.2Hz,1H),7.20(dd,J=8.1,7.5H z,1H),7.17(dq,J=7.9,0.9Hz,1H),7.01(ddq,J=8.1,2.1,0.9Hz,1H),6.89(dp,J=1.9,0.9Hz,1 H),6.81(ddd,J=7.3,1.8,1.1Hz,1H),5.02(t,J=1.0Hz,2H),4.14(dt,J=13.3,6.6Hz,1H),4.06 (dt,J=13.2,6.7Hz,1H),3.81(s,3H),2.93(t,J=6.7Hz,2H),2.28(d,J=1.1Hz,3H),2.23(s,3H) .
[0501] Synthesis of Compound Z86: Z86-A and sodium acetate borohydride were placed in a two-necked flask. Under nitrogen, anhydrous dichloromethane was added to dissolve the mixture, followed by the addition of cyclohexanone. The reaction was allowed to proceed overnight at room temperature. After stirring for half an hour with saturated sodium bicarbonate solution, the mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, and the organic solvent removed by rotary evaporation. Purification by column chromatography yielded Z86 as a white solid. 1 H NMR(500MHz, CDCl3) δ7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.2Hz,1H),7.20(dd,J=8.1,7.5Hz,1H),7.17 (dq,J=7.9,0.9Hz,1H),7.01(ddq,J=8.1,2.1,0.9Hz,1H),6.89(tt,J=2.0,0.9Hz,1H),6.81(ddd,J=7.3,1. 8,1.1Hz,1H),5.02(s,2H),3.81(s,3H),3.56(dd,J=15.4,5.9Hz,1H),3.48(dd,J=15.3,5.9Hz,1H),2.78( dp,J=6.6,4.6Hz,1H),2.60(dt,J=6.6,5.9Hz,1H),2.28(d,J=1.1Hz,3H),2.23(s,3H),1.72–1.31(m,10H).
[0502] Example 87
[0503] The synthesis method of compound Z87 refers to the synthesis of Z86, except that the cyclohexanone in the synthesis process of Z86 is replaced by tetrahydro-pyran-4-one, and the resulting NMR 1H NMR (500MHz, CDCl3) δ7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.2Hz,1H),7.20(dd,J=8.1,7.5Hz,1H),7.17(dq,J=7.9,1.0Hz,1H),7 .01(ddq,J=8.1,2.1,0.9Hz,1H),6.89(dp,J=2.0,1.0Hz,1H),6.81(ddd,J=7.3,1.8,1.1Hz,1H),5.02(s,2H),3.81(s,2H),3.68–3.6 2(m,1H),3.65–3.61(m,1H),3.57(ddd,J=12.3,5.8,3.1Hz,3H),3.48(dd,J=15.3,5.9Hz,1H),2.92(dp,J=6.4,4.8Hz,1H),2.70(q,J =6.0Hz,1H),2.28(d,J=1.1Hz,3H),2.23(s,1H),1.83(dddd,J=12.4,5.9,4.8,3.2Hz,2H),1.59(dddd,J=12.4,5.7,4.8,3.2Hz,2H).
[0504] Example 88
[0505] The synthesis method of compound Z88 refers to the synthesis of Z86, except that the cyclohexanone in the synthesis process of Z86 is replaced by tetrahydropyran-4-carboxaldehyde, and the resulting NMR 1 H NMR(500MHz, CDCl3)δ7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.2Hz,1H),7.24–7.14(m,2H),7.01(ddq,J=8.1,2.1,0.9H z,1H),6.89(dp,J=2.0,1.0Hz,1H),6.81(ddd,J=7.3,1.8,1.1Hz,1H),5.02(s,2H),3.81(s,2H),3.65–3.60(m,1H),3.6 0(d,J=4.9Hz,2H),3.58(s,1H),3.57–3.53(m,1H),3.57–3.50(m,1H),3.26(p,J=6.2Hz,1H),2.80(ddd,J=12.8,6.0,4. 4Hz, 1H), 2.67 (ddd, J=12.8, 6.0, 4.5Hz, 1H), 2.28 (d, J=1.1Hz, 3H), 2.23 (s, 1H), 1.79–1.68 (m, 3H), 1.57–1.46 (m, 2H).
[0506] Example 89
[0507] The synthesis method of compound Z89 refers to compound Z82, except that Z82-D in the synthesis process of Z82 is replaced by 1-methylpiperidine-4-carboxylic acid, and piperidine is replaced by Z86-A. 1 HNMR(500MHz, CDCl3)δ7.75(t,J=6.3Hz,1H),7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.2Hz,1H),7.23–7.13( m,2H),7.01(ddq,J=8.1,2.1,1.0Hz,1H),6.89(tt,J=2.0,1.0Hz,1H),6.81(ddd,J=7.3,1.8,1.1Hz,1H),5.0 4(t,J=1.0Hz,2H),4.02(d,J=6.4Hz,2H),3.81(s,2H),2.76(ddd,J=12.3,8.8,6.1Hz,2H),2.52(ddd,J=12.5 ,8.8,6.2Hz,2H),2.39(p,J=5.5Hz,1H),2.28(d,J=1.1Hz,3H),2.27(s,3H),2.23(s,3H),1.89–1.73(m,4H).
[0508] Test Example 1: Determination of the inhibitory activity of compounds on human MDA-MB-231 breast cancer cells and MCF-10A normal breast epithelial cells
[0509] The present invention uses human MDA-MB-231 breast cancer and MCF-10A normal breast epithelial cell lines to detect antitumor activity, and the drug concentration gradient is set at 0, 0.1 μM, 0.2 μM, 0.4 μM, 0.8 μM, and 1 μM, with a concentration of 3×10 3 Cells / well were seeded in a 96-well plate. Cell activity was detected using the CCK-8 assay 72 hours after drug treatment, and the half-maximal inhibitory concentration was determined. That is, after treatment, 10 μM CCK-8 reagent was added to each well, incubated for 2 hours, and the absorbance was read at a wavelength of 450 nm. The results are shown in Tables 1 and 2.
[0510] As shown in Table 1, 1,2,4-triazine-3,5(2H,4H)-dione compounds all showed good inhibitory activity against triple-negative breast cancer MDA-MB-231 cells, while the carboxamide derivative Z13 in which both R1 and R2 were H completely lost its activity, suggesting the importance of the 6-substituted amide structure of 1,2,4-triazine-3,5(2H,4H)-dione in inhibiting the activity of triple-negative breast cancer MDA-MB-231 cells.
[0511] Table 1 Inhibitory effect of compounds on breast cancer MDA-MB-231 cells at a concentration of 20 μM
[0512] Among them, *** represents a strong inhibition rate, that is, an inhibition rate of more than 80%; ** represents a moderate inhibition rate, that is, an inhibition rate of 60-80%; * represents a low inhibition rate, that is, an inhibition rate of 40-60%; NA represents no activity, that is, an inhibition rate of less than 30%. Asterisks are used to make the technical effects of the present invention more intuitive and clear.
[0513] As shown in Table 2, the IC values of representative compounds were tested against triple-negative breast cancer cells MDA-MB-231 and normal breast cancer cells MCF-10A. 50 Activity. The literature shows that the IC of paclitaxel against MDA-MB-231 50 =1μM (Cong HJ et al. J Nat Prod. 2013), IC for MCF-10A 50 =5.64nM (Journal of Cellular Physiology (2019), 234, (4), 4277-4290). Compared with paclitaxel, the compounds protected by the present invention have higher MDA-MB-231 cell inhibitory activity, that is, stronger in vitro anti-tumor inhibitory activity, especially the activity of compound Z37 is around 100nM, while the activity against MCF-10A cells is weak (IC 50 >10 μM), indicating that 1,2,4-triazine-3,5(2H,4H)-dione compounds exhibited strong antitumor activity and low toxicity. Furthermore, as shown in Figure 4A, representative compounds Z19 and Z37 also exhibited strong cytotoxicity against other breast cancer cells.
[0514] Table 2 Inhibitory activity of representative compounds against breast cancer MDA-MB-231 cells and normal breast cells MCF-10A cells
[0515] Test Example 2: Determination of the binding activity of compounds to eEF2K
[0516] The present invention uses the SPR method (surface plasmon resonance method) to detect the binding ability of Z1-E, Z4, Z5, Z42, Z12, Z14, and Z18 to eEF2K. The SPR experiment was performed using Amersham Life Sciences 110397-04. 1 mM / L of the compound was prepared in DMSO and immobilized on the photocrosslinker SensorCHIPTM. The eEF2K protein was diluted with PBST to concentrations of 200 nM, 400 nM, 1600 nM, and 3200 nM, respectively, and PBST was used as the running buffer. The eEF2K protein was injected at a flow rate of 0.5 μL / s for 600 s. The experiment was performed from low concentration to high concentration; the regeneration solution glycine hydrochloride (pH = 2.0) was used for regeneration at a flow rate of 2 μL / s. The detection time for the dissociation process was 360 s. The laboratory temperature was 4°C. The raw data collected on the SPR biosensor were further processed to eliminate any artifacts, such as nonspecific binding and differences in buffer composition. The results are shown in Figure 4C. As shown, representative compounds Z4, Z5, Z42, Z12, Z14, and Z18 exhibited strong binding to eEF2K, indicating that the compounds selectively targeted the eEF2K protein.
[0517] Test Example 3: Determination of the degradation activity of compounds on eEF2K
[0518] The present invention used western blotting to examine the effects of different concentrations of Z19 and Z37 on eEF2K protein expression in MDA-MB-231 and BT549 cells. The specific steps were as follows: After treatment with different concentrations of Z19 and Z37 (0, 50 nM, 100 nM, 200 mM, 400 mM, and 800 nM) for 48 hours, the cells were lysed with RIPA buffer containing a protease inhibitor cocktail and a phosphatase inhibitor. The cell lysate was centrifuged at 12,000 × g for 15 minutes at 4°C. The protein concentration of the supernatant was determined by the Bradford assay. A total of 20 g of protein sample was subjected to SDS-PAGE and transferred to a PVDF membrane (0.22 μm, Merek Millipore). After blocking with skim milk, the membrane was incubated with the corresponding primary antibody and then with a secondary antibody conjugated to HRP. Protein signals were detected using an enhanced chemiluminescence kit. The results are shown in Figure 4B, where it can be clearly seen that Z19 and Z37 inhibited the expression of eEF2K protein in a dose-dependent manner.
[0519] In addition, the effects of compounds Z1, Z4, Z15, Z16, Z17, Z18, Z19, Z23, Z24, Z28, Z45, Z53, Z59, Z63, Z73, Z74, Z75, Z76, Z77, Z78, Z79, and Z80 on eEF2K protein expression in MDA-MB-231 cells at a 1 uM concentration were determined using the above method. As shown in Table 3, almost all of the compounds of the present invention inhibited eEF2K protein expression.
[0520] Table 3 Degradation rate of eEF2K protein in breast cancer MDA-MB-231 cells by compounds at 1 μM concentration
[0521] Among them, *** represents a strong degradation rate, i.e., a degradation rate of more than 70%; ** represents a moderate inhibition rate, i.e., an inhibition rate of 50-70%; * represents a low inhibition rate, i.e., an inhibition rate of 20-50%; and NA represents no activity, i.e., an inhibition rate of less than 20%. Asterisks are used to make the technical effects of the present invention more intuitive and clear.
[0522] Test Example 4: Animal experiment on the anti-tumor activity of the compound.
[0523] The present invention uses paclitaxel (PTX) as a positive control to determine the effect of compound Z19 at doses of 5 mg / kg and 10 mg / kg on tumor proliferation. The specific experimental steps are as follows: MDA-MB-231 cells (1×106 / mouse) were suspended in 100 μL DMEM and then subcutaneously injected into the right side of 4-week-old female nude mice. Each group had six mice. Tumor-bearing mice were randomly divided into groups. When the tumor size reached 70-80 mm 3 Treatment began at 40°C (volume = length × width 2 × π / 6). Mice were randomly divided into groups and treated over the next 16 days. Tumor volume and mouse body weight were measured every other day. The results, as shown in Figure 5A and B, show that compound Z19 exhibited similar efficacy to PTX at the same dose. Furthermore, with prolonged treatment, compound Z19 demonstrated superior antitumor efficacy compared to PTX.
[0524] In addition to determining the anti-tumor activity of the compounds, the toxicity and side effects of compound treatment on the experimental animals were also assessed. The results, shown in Figures 5C and 5D, indicate that compound Z19 exhibited no significant toxicity or side effects. No significant lesions in the heart, liver, spleen, lungs, or kidneys were observed in the Z19-treated mice. Regarding weight changes, mice in the PTX group experienced significant weight loss over time. No weight loss was observed in either the 5 mg / kg or 10 mg / kg Z19 groups.
[0525] In summary, the diketone compounds (1,2,4-triazine-3,5(2H,4H)-dione compounds) disclosed in the present invention exhibit strong anti-malignant tumor cell activity by targeting the eEF2K protein while having little effect on normal cell activity, showing strong anti-tumor potential and high safety, and therefore have great application prospects.
[0526] Obviously, the above embodiments are merely examples for clarity of explanation and are not intended to limit the implementation methods. Those skilled in the art will appreciate that other variations or modifications can be made based on the above description. It is not necessary and impossible to enumerate all implementation methods here. Obvious variations or modifications arising therefrom remain within the scope of protection of the present invention.
Claims
1. A diketone compound, It is characterized in that The structural formula of the diketone compound is shown in Formula A: in, are independently selected from substituted or unsubstituted aryl or heteroaryl; X is carbonyl or alkyl; Y is substituted or unsubstituted alkyl; Z is N or CH; R 1 and R 2 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclic, ester group, substituted or unsubstituted alkenyl group, substituted or unsubstituted alkynyl group, substituted or unsubstituted aryl group, both of which cannot be hydrogen at the same time; or R 1 and R 2 Together with the nitrogen atom to which they are attached, they form a substituted or unsubstituted heterocyclic group; R 1 and R 2 Can be the same or different.
2. The diketone compound according to claim 1, It is characterized in that The R 1 and R 2 By several R 3 replaced; said R 3 One or more selected from halogen, C1-C6 alkyl, haloalkyl, silane, aralkyl, heteroaryl, alkoxy, hydroxy, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminealkyl, aminealkoxy, amino, alkylamino, hydroxyalkylamino, aminealkylamino, alkoxyacyl, alkoxycarbonylamino, cyano, acyloxy, acyl, sulfonyl, carbamoyl, sulfonylamino, urea, nitro, thiourea; in the substituted or unsubstituted alkyl, the alkyl has 1 to 10 carbon atoms; in the substituted or unsubstituted heterocyclic, the heterocyclic has 3 to 8 members Monocyclic or 6-20 membered polycyclic; in substituted alkyl, substituted heterocyclic, substituted alkenyl, substituted alkynyl, and substituted aryl, the substituents are independently selected from one or more of halogen, alkyl, alkoxy, haloalkyl, silyl, aralkyl, heteroaryl, hydroxyl, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminealkyl, aminealkoxy, amino, alkylamino, hydroxyalkylamino, aminealkylamino, alkoxyacyl, alkoxycarbonylamino, sulfonylamino, urea, thiourea, cyano, nitro, acyloxy, acyl, sulfonyl, and carbamoyl.
3. The diketone compound according to claim 1, It is characterized in that The substituted or unsubstituted aryl or heteroaryl group is a substituted or unsubstituted benzene ring, a naphthalene ring, a biphenyl ring, or an aromatic heterocycle composed of one or more N, O, and S. In the substituted or unsubstituted aryl or heteroaryl group, the substituent groups include one or more of hydrogen, alkyl, haloalkyl, silane, aralkyl, heteroaryl, alkoxy, haloalkoxy, hydroxyl, hydroxyalkoxy, hydroxyalkyl, alkoxyalkoxy, alkoxyalkyl, aminealkoxy, amino, aminealkyl, alkylamino, hydroxyalkylamino, aminealkylamino, alkoxyacyl, alkoxycarbonylamino, sulfonylamino, urea, thiourea, halogen, cyano, acyloxy, nitro, carbamoyl, acyl, and sulfonyl.
4. The diketone compound according to claim 3, It is characterized in that The substituted or unsubstituted heteroaryl group is selected from one or more of a substituted or unsubstituted pyrrole ring, a pyrazole ring, a furan ring, a thiophene ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an imidazole ring, a pyridine ring, a pyrazine ring, a pyrimidine ring, a pyridazine ring, a triazole, a naphthalene ring, a benzoaromatic heterocycle, and a benzocycloalkane.
5. The diketone compound according to claim 1, It is characterized in that The diketone compound is the following compound:
6. A method for preparing a diketone compound as claimed in any one of claims 1 to 5, It is characterized in that The invention comprises the following preparation methods: Method 1: (1) reacting the compound represented by formula A1 with the compound represented by formula A2 by diazotization coupling reaction to obtain the compound represented by formula A3; (2) The compound represented by formula A3 is subjected to ring closure under acidic conditions to obtain the compound represented by formula A4, and the compound represented by formula A4 undergoes substitution reaction with a halogenated hydrocarbon under alkaline conditions to obtain the compound represented by formula A5; (3) The cyano group of the compound represented by formula A5 is hydrolyzed under acidic conditions to obtain a compound represented by formula A6 containing a carboxylic acid; (4) the compound represented by formula A6 is prepared into an acyl chloride compound represented by formula A7, and reacted with an amine compound to obtain a compound represented by formula A, i.e., the diketone compound; Or method 2: (1) reacting the compound represented by formula B1 with the compound represented by formula B2 to obtain the compound represented by formula B3; (2) the compound represented by formula B3 reacts under alkaline conditions to obtain the compound represented by formula B4, and the compound represented by formula B4 reacts to obtain the compound represented by formula B5; (3) the compound represented by formula B5 is reacted to obtain the compound represented by formula B6 containing carboxylic acid; or the compound represented by formula B5 is reacted with an amine compound to obtain the diketone compound; (4) reacting the compound represented by formula B6 with an amine compound to prepare the diketone compound; Or method three: (1) reacting the cyano group of the compound represented by formula A5 to obtain the compound represented by formula C2 containing an amine group; (2) preparing the diketone compound from the compound represented by formula C2; The structural formula of the above compound is as follows: The structural formula of the amine compound is shown below:
7. The preparation method according to claim 6, It is characterized in that In method one, the molar ratio of the compound represented by formula A1 to the compound represented by formula A2 is 1:1-1:2, the acidic condition is a pH value of 1-4; the alkaline condition is a pH value of 8-10, and the compound represented by formula A6 is subjected to an acyl chloride reaction under the action of a catalyst to prepare an acyl chloride compound represented by formula A7; in method two, the reaction of the compound represented by formula B1 and the compound represented by formula B2 is carried out under a copper salt catalyst and an alkali catalyst, the compound represented by formula B3 is reacted under an inorganic alkali compound condition to obtain a compound represented by formula B4, and the compound represented by formula B4 is reacted under a phosphorus catalyst to obtain a compound represented by formula B5; in method three, the cyano group of the compound represented by formula A5 is reacted under hydrogen and a noble metal catalyst to obtain an amine-containing compound represented by formula C2, the compound represented by formula C2 is reacted with an amine compound to prepare the diketone compound, or the compound represented by formula C2 is reacted with a carboxylic acid compound to prepare the diketone compound.
8. An anti-tumor drug, It is characterized in that The active ingredient of the anti-tumor drug comprises the diketone compound and its isomer or pharmaceutically acceptable salt or hydrate according to any one of claims 1 to 5.
9. Use of the diketone compound and its isomers or pharmaceutically acceptable salts or hydrates according to any one of claims 1 to 5 in the preparation of malignant tumor drugs or in the preparation of eukaryotic elongation factor kinase 2 inhibitors.
10. The use according to claim 9, It is characterized in that The malignant tumor is selected from triple-negative breast cancer, esophageal cancer, lung cancer, colon cancer, breast cancer, rectal cancer, liver cancer, gastric cancer, thyroid cancer, prostate cancer, cervical cancer, uterine cancer, pancreatic cancer, ovarian cancer, bladder cancer, brain tumor, blood tumor, lymphoma, etc.
Citation Information
Patent Citations
Novel triazinedione derivatives as GABAB receptor modulators
CN101679354A
Substituted uracils as chymase inhibitors
CN105873919A
Polysubstituted uracil derivative and application thereof
CN114671856A
Quinoline compound composing 1,2,4-triazine-dione and use thereof
US20130252958A1
